**Title:** BACITRACIN-ALGINATE OLIGOMER CONJUGATES

**Abstract:** The invention provides abacitran-alginic acid oligomer conjugate comprising a bacitracin-class antibiotic connected covalently to at least one alginic acid oligomer via a direct covalent bond or a covalent molecular linker, or a pharmaceutically acceptable salt, solvate, hydrate, diastereoisomer, tautomer, enantiomer or active metabolite thereof. Also provided are methods for the preparation of said conjugate, pharmaceutical compositions comprising said conjugate and the use thereof in a method for the treatment or prevention of a bacterial infection in a subject with, suspected to have, or at risk of, a bacterial infection.
Bacitracin-alginate oligomer conjugates

The present invention provides a novel modified form of bacitracin-class antibiotics having advantageous properties. In particular, it has been found that by providing bacitracin-class antibiotics as conjugates with alginate oligomers, the spectrum of activity of the antibiotic, which typically in unconjugated form is restricted to gram-positive bacteria, may surprisingly be broadened to include gram-negative bacteria. The invention is accordingly directed to providing medical uses and methods using bacitracin-alginate oligomer conjugates in the treatment or prevention of bacterial infections. The invention further provides methods for preparing the conjugates of the invention.

The therapeutic use of known bacitracin-class antibiotics is presently restricted to the treatment of infections with Gram positive bacteria because such antibiotics have only very limited, if any, efficacy against Gram negative bacteria. Any effectiveness against Gram negative bacteria which may be observed experimentally is typically so slight that the amounts required to exert a therapeutic effect would give rise to unacceptable side effects. It has now been observed that covalently conjugating alginate oligomers to bacitracin-class antibiotics widens the spectrum of therapeutically useful activity against bacteria species such to include Gram negative bacteria. In other words bacitracin-alginate oligomer conjugates are a class of novel chemical entities having therapeutically useful antibacterial efficacy against both Gram negative and Gram positive bacteria. The bacitracin-alginate oligomer conjugates of the invention therefore represent improved therapeutic agents for the treatment or prevention of bacterial infections in animal subjects.

Bacitracin-class antibiotics are a well-known and well-characterised class of cyclic polypeptide antibiotics that inhibit synthesis of the bacterial cell wall (Ming, L-J., et al., 2002, Journal of Inorganic Chemistry, Vol 91(1):46-58, which is herein incorporated by reference in its entirety). Bacitracin was initially isolated from cultures of *Bacillus subtilis* and *Bacillus licheniformis* and it has since been found that this isolate is a complex mixture of structurally similar dodecapeptide congeners. The most prevalent congeners in such isolates have to date been termed bacitracin A1, A2, B1, B2, B3, C, D1, D2, D3, E, F, G, H1, H2, H3, I1, I2, I3, and X. Bacitracin A1, A2, B1, B2, B3, C, D1, D2, D3 and E are considered to have
the greatest antibiotic efficacy and natural bacitracin preparations are typically comprised predominantly of bacitracin A and bacitracin B.

The bacitracin-class antibiotics maybe described generally as branched cyclic dodecapeptides, more specifically heptacyclic peptides having a pentapeptide side chain, which demonstrate antibiotic efficacy, believed to be primarily by virtue of the inhibition of bacterial cell wall synthesis. More specifically, it is believed that bacitracin-class antibiotics bind undecaprenyl pyrophosphate which prevents the recycling of this sugar carrier during peptidoglycan synthesis and this in turn inhibits bacterial cell wall synthesis. Gram positive species may have cell walls containing as much as 90% peptidoglycan whereas Gram negative species may have as little as 10%. This is believed to explain bacitracin's apparent selective antibacterial effects against Gram negative and Gram positive species. Antibacterial activity is dependent on complexing with divalent metal cations, e.g. Zn\(^{2+}\), Mg\(^{2+}\), Mn\(^{2+}\), and Co\(^{2+}\). As such, derivatives carrying a variety of metal chelating groups have been proposed (WO 97/47313).

Functionally, the class is very effective against Gram positive bacteria, especially Gram-positive bacilli and cocci including *Staphylococcus*, *Streptococcus*, *Bacillus*, *Micrococcus* and *Clostridium*. In contrast, efficacy against Gram negative bacteria is very limited and usually to the extent that the amounts required for therapeutic effectiveness are associated with typically unacceptable side effects. Systemic use is however associated with toxicity issues (that is toxicity to the subject or "host" to whom the bacitracin-class antibiotic is administered, namely "host toxicity"), in particular nephrotoxicity. Localised topical use and oral use to treat GI infections (bacitracin is poorly absorbed from the GI tract) is less therefore less problematic.

There is an on-going need for new antibiotics and also ways to make existing antibiotics more flexible to use.

Alginate oligomers have been described in the literature at length. Briefly, alginates are linear polymers of (1-4) linked β-D-mannuronic acid (M) and/or its C-5 epimer α-L-guluronic acid (G). The primary structure of alginates can vary greatly. The M and G residues can be organised as homopolymeric blocks of contiguous M or G residues, as blocks of alternating M and G residues and single M or G residues can be found interspacing these block structures. An alginate molecule can comprise some or all of these structures and such structures might not be uniformly distributed throughout the polymer. In the extreme, there exists a
homopolymer of guluronic acid (polyguluronate) or a homopolymer of mannuronic acid (polymannuronate). Alginate oligomers may be obtained from alginate polymers which are typically isolated from natural sources as large high molecular weight polymers (e.g. an average molecular weight in the range 300,000 to 500,000 Daltons). Such large alginate polymers may be degraded, or broken down, e.g. by chemical or enzymatic hydrolysis to produce alginate structures of lower molecular weight.

As shown in the Examples, it has now been found that covalent conjugation of bacitracin-class antibiotics to alginate oligomers creates a novel chemical entity with antibacterial efficacy against Gram-negative bacteria.

Accordingly, in a first aspect the invention provides a bacitracin-alginate oligomer conjugate comprising a bacitracin-class antibiotic connected covalently to at least one alginate oligomer via a direct covalent bond or a covalent molecular linker.

The bacitracin-alginate oligomer conjugates may also be described by Formula I:

\[ B-(L-A)_n \]  

(I)

wherein B- is a bacitracin-class antibiotic, L is a direct covalent bond or a covalent molecular linker, -A is an alginate oligomer and n is an integer of 1 to 10, e.g. 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 2 or 1.

In accordance with the invention a bacitracin-class antibiotic is broadly defined as a cyclic dodecapeptide which demonstrates antibacterial efficacy wherein said peptide consists of a heptacyclic peptide with a pentapeptide side chain. Specifically contemplated herein are naturally occurring bacitracins or functionally equivalent derivatives thereof which retain antibacterial efficacy, including fully and semi-synthetic forms. Thus included with the term bacitracin-class antibiotic are bacitracin A1, A2, B1, B2, B3, C, D1, D2, D3, E, F, G, H1, H2, H3, i1, i2, i3, and X, e.g. as described, inter alia, in Ming, L-J., et al., supra, and Economou, N.J., et al, 2013, Vol 110, 14207-14212. Functionally equivalent derivatives are described in, inter alia, WO 97/47313, WO 201 1/051073 and WO 201 1/051071.

By way of example a bacitracin-class antibiotic may be represented by Formula II.
wherein Leu is leucine; Glu is glutamic acid; Lys is lysine; Orn is ornithine; Phe is phenylalanine; His is histidine; Asp is aspartic acid; Asn is asparagine;
Y is valine, isoleucine, leucine or 5-methylene-isoleucine;
Z is valine, isoleucine, leucine or 5-methylene-isoleucine; and
X is W[II]-Cys[II] or V[II]-Thz[II]; wherein
W is valine, isoleucine, leucine or 5-methylene-isoleucine and Cys is cysteine; and
V is

H₂N-C(R)H-

wherein R is the a side chain of valine, isoleucine, leucine or 5-methylene-isoleucine; and

Thz is a thiazoline ring ( ) which is 2’ coupled to V and 4’ coupled to the a-carbon of Leu[II].

In Formula II the ε-amine of Lys[II] is coupled to the ocarboxyl group of Asn[II] by a peptide bond.

In accordance with the invention references to bacitracin-class antibiotics extend to antibacterial derivatives of Formula II, i.e. functionally equivalent derivatives which retain (e.g. have at least 70%, 80%, 90% or 95% of the) antibacterial efficacy of bacitracin A1 and/or A2, wherein one or more, of amino acids Leu[II], Glu[II], Orn[II], Phe[II], His[II] or Asp[II] is replaced by another amino acid residue which may be selected from natural or non-genetically encoded amino acids, e.g. leucine, threonine, acid, phenylalanine, arginine, histidine, lysine, asparagine, serine, cysteine, homolysine, ornithine, diaminobutyric acid (e.g. α,γ-diaminobutyric acid), diaminopimelic acid, diaminopropionic acid, homoarginine, trimethyllysine, trimethylornithine, 4-aminopiperidine-4-carboxylic acid, 4-amino-1-carbamimidoylpiperidine-4-carboxylic acid and 4-guanidinophenylalanine.
In accordance with the invention references to bacitracin-class antibiotics extend to antibacterial equivalents of Formula II, i.e. functional equivalents which retain (e.g. have at least 70%, 80%, 90% or 95% of the) antibacterial efficacy of bacitracin A1 and/or A2, wherein Thz is substituted with a fluorine, chlorine or bromine, or a linear or branched aliphatic unsaturated or saturated Ci-C4 alkyl or alkoxy group, e.g. methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, ethylene, propylene, butylene, hydroxy, methoxy, ethoxy, propoxy, iso-propoxy, butyloxy group, iso-butyloxy, sec-butyloxy, tert-butyloxy or halogen substituted versions thereof.

Preferably the substituting amino acid is an amino acid with a cationic side chain, i.e. an amino acid that has a side chain that has a net positive charge at the intracellular pH of a tumour cell, e.g. around pH 7.4. Of the genetically coded amino acids this would include lysine and arginine but any non-genetically coded or modified amino acid carrying such a net positive charge on its side chain may be used, e.g. those amino acids carrying a side-chain with a guanidino group or an amine group or another cationic moiety, e.g. derivatives of lysine, and arginine in which any hydrogen in the side chain, except the protonating hydrogen, is substituted with a halogen atom, e.g. fluorine, chlorine or bromine, or a linear, branched aliphatic unsaturated or saturated C1-C4 alkyl or alkoxy group, e.g. methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, ethylene, propylene, butylene, hydroxy, methoxy, ethoxy, propoxy, iso-propoxy, butyloxy group, iso-butyloxy, sec-butyloxy, tert-butyloxy or halogen substituted versions thereof. Suitable non-genetically coded amino acids with cationic side chains include homolysine, ornithine, diaminobutyric acid, diaminopimelic acid, diaminopropionic acid and homoarginine as well as trimethyllysine and trimethylornithine, 4-aminopiperidine-4-carboxylic acid, 4-amino-1-carbamimidopiperidine-4-carboxylic acid and 4-guanidinophenylalanine.

An amino acid is a molecule containing an amine group, a carboxylic acid group and at least one carbon separating these two groups. Other groups may be attached to the separating carbon(s). These groups may be referred to as "side-chains" although at its most simple the side chains could be hydrogen (glycine). Amino acids with a single separating carbon are termed "oarmino acids" and have the generic formula H2NCR1R2COOH, where R1 and R2 are substituent groups, i.e. are side-chains. The separating carbon is known as the a-carbon. Other types of amino acid exist where the amino and carboxylic acid groups are separated by
more than a single carbon atom; for example, in β-amino acids the carbon atom to which the amino group is separated from the carboxylic acid group by two carbon atoms and in γ-amino acids three carbon atoms separate the amino and carboxylic acid groups. Preferably the amino acids in the bacitracin-class antibiotic of use in the invention will be α, β or γ-amino acids, more preferably α or β-amino acids and most preferably γ-amino acids.

Amino acids, with the exception of glycine, may exist as two or more stereoisomers. In particular the carbon of an amino acid other than glycine is a chiral centre and so gives rise to two enantiomeric forms of each amino acid. These forms are often referred to as D and L forms, e.g. D-alanine and L-alanine. Amino acids with further chiral centres will exist in four or more possible stereoisomers, e.g. threonine has two chiral centres and so may exist in one of four stereoisomeric forms. Any stereoisomeric form of an amino acid may be present the bacitracin-class antibiotic molecules of use in the invention. For the purposes of describing the present invention, where the term "non-genetically encoded" is applied to amino acids, this does not include the D forms of amino acids that occur in nature in the L form.

In preferred embodiments the bacitracin-class antibiotic is selected from bacitracin A 1, A 2, B 1, B 2, B 3, C, D 1, D 2, D 3, E, F, G, H 1, H 2, H 3, I 1, I 2, I 3, and X, more preferably selected from A 1, A 2, B 1, B 2, B 3, C, D 1, D 2, D 3 and E, and more preferably from bacitracin A (A 1 and/or A 2) and bacitracin B (B 1 and/or B 2). These bacitracins may be represented by Formula III:

\[
\text{R-L-Leu-D-Glu-L-Y-L-Lys-D-Orn-L-Z-D-Phe-L-His-D-Asp-L-Asn (II)}
\]

wherein

![Chemical structure of bacitracin molecules](attachment:image.png)
In accordance with the invention preferred bacitracin-class antibiotics are functionally equivalent derivatives of the bacitracins mentioned immediately above i.e. functional equivalents which retain (e.g. have at least 70%, 80%, 90% or 95% of the) the antibacterial efficacy of the bacitracin in question.

In certain embodiments the bacitracin-class antibiotic may be complexed with divalent metal cations, e.g. Zn$^{2+}$, Mg$^{2+}$, Mn$^{2+}$, and Co$^{2+}$.

In certain embodiments one or more free amine groups in the bacitracin-class antibiotic may be masked by modification, e.g. by sulfomethylation.

As noted above, alginates typically occur as polymers of an average molecular mass of at least 35,000 Daltons, i.e. approximately 175 to approximately 190 monomer residues, although typically much higher. An alginate oligomer according to the present invention will, on the other hand, contain 2 to 100 monomer residues, more typically 3, 4, 5 or 6 to 100, and may contain 2, 3, 4, 5 or 6 to 75, 2, 3, 4, 5 or 6 to 50, 2, 3, 4, 5 or 6 to 40, 2, 3, 4, 5 or 6 to 35 or 2, 3, 4, 5 or 6 to 30 residues. Thus, an alginate oligomer for use according to the invention will typically have an average molecular weight of 350, 550, 700, 900 or 1000 to 20,000 Daltons, 350, 550, 700, 900 or 1000 to 15,000 Daltons, 350, 550, 700, 900 or 1000

<table>
<thead>
<tr>
<th>Bacitracin</th>
<th>R</th>
<th>L-Y</th>
<th>L-Z</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>R₁</td>
<td>Ile</td>
<td>Ile</td>
</tr>
<tr>
<td>A2</td>
<td>R₂</td>
<td>Ile</td>
<td>Ile</td>
</tr>
<tr>
<td>B1</td>
<td>R₃</td>
<td>Ile</td>
<td>Ile</td>
</tr>
<tr>
<td>B2</td>
<td>R₁</td>
<td>Val</td>
<td>Ile</td>
</tr>
<tr>
<td>B3</td>
<td>R₁</td>
<td>Ile</td>
<td>Val</td>
</tr>
<tr>
<td>D1</td>
<td>R₃</td>
<td>Val</td>
<td>Ile</td>
</tr>
<tr>
<td>D2</td>
<td>R₃</td>
<td>Ile</td>
<td>Val</td>
</tr>
<tr>
<td>D3</td>
<td>R₁</td>
<td>Val</td>
<td>Val</td>
</tr>
<tr>
<td>E</td>
<td>R₃</td>
<td>Val</td>
<td>Val</td>
</tr>
<tr>
<td>F</td>
<td>R₄</td>
<td>Ile</td>
<td>Ile</td>
</tr>
<tr>
<td>H1</td>
<td>R₅</td>
<td>Ile</td>
<td>Ile</td>
</tr>
<tr>
<td>H2</td>
<td>R₄</td>
<td>Val</td>
<td>Ile</td>
</tr>
<tr>
<td>H3</td>
<td>R₄</td>
<td>Ile</td>
<td>Val</td>
</tr>
<tr>
<td>I1</td>
<td>R₅</td>
<td>Val</td>
<td>Ile</td>
</tr>
<tr>
<td>I2</td>
<td>R₅</td>
<td>Ile</td>
<td>Val</td>
</tr>
<tr>
<td>I3</td>
<td>R₄</td>
<td>Val</td>
<td>Val</td>
</tr>
</tbody>
</table>
to 10,000 Daltons, 350, 550, 700, 900 or 1000 to 8000 Daltons, 350, 550, 700, 900 or 1000 to 7000 Daltons, or 350, 550, 700, 900 or 1000 to 6000 Daltons.

Alternatively put, the alginate oligomer may have a degree of polymerisation (DP), or a number average degree of polymerisation (DPn) of 2 to 100, preferably 2 to 75, preferably 2 to 50, more preferably 2 to 40, 2 to 35, 2 to 30, 2 to 28, 2 to 25, 2 to 22, 2 to 20, 2 to 18, 2 to 17, 2 to 15 or 2 to 12.

Other representative ranges (whether for the number of residues, DP or DPn) include any one of 3, 4, 5, 6, 7, 8, 9, 10 or 11 to any one of 50, 45, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13 or 12.

Other representative ranges (whether for the number of residues, DP or DPn) include any one of 8, 9, 10, 11, 12, 13, 14 or 15 to any one of 50, 45, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17 or 16.

Other representative ranges (whether for the number of residues, DP or DPn) include any one of 11, 12, 13, 14, 15, 16, 17 or 18 to any one of 50, 45, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19 or 18.

It may in some embodiments be advantageous to select a larger alginate oligomer so as to create a conjugate of greater size. Larger conjugates may help deliver the bacitracin-class antibiotics selectively to sites and locations of infection because the vascular permeability of such areas within a subject is typically greater than in the vasculature of non-infected areas. Consequently larger conjugates are less likely to enter non-infected areas from the bloodstream, but would able to enter the more permeable infected areas. A representative size range for such a larger oligomer may for example be 20 to 100 residues (or DP or DPn of 20 to 100) or any one of 20, 21, 22, 23, 24 or 25, to any one of 100, 90, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35 or 30 residues (or DP or DPn of any one of these ranges) or any one of 30, 31, 32, 33, 34 or 35, to any one of 100, 90, 80, 75, 70, 65, 60, 55, 50, 45 or 40 residues (or DP or DPn of any one of these ranges). Alternatively, these results might be also be achieved by increasing the numbers of alginate oligomers, even those of smaller size, in the conjugate.

An alginate oligomer will, as noted above, contain (or comprise) guluronate or guluronic acid (G) and/or mannurionate or mannuronic acid (M) residues or units. An alginate oligomer according to the invention will preferably be composed solely, or substantially solely (i.e. consist essentially of) uronate/uronic acid residues, more
particularly solely or substantially solely of G and/or M residues. Alternatively expressed, in the alginate oligomer of use in the present invention, at least 80%, more particularly at least 85, 90, 95 or 99% of the monomer residues may be uronate/uronate acid residues, or, more particularly G and/or M residues. In other words, preferably the alginate oligomer will not comprise other residues or units (e.g. other saccharide residues, or more particularly other uronic acid/uronate residues).

The alginate oligomer is preferably a linear oligomer.

More particularly, the alginate oligomers proposed for use according to the present invention will contain at least 70% G residues (i.e. at least 70% of the monomer residues of the alginate oligomer will be G residues). Specific embodiments thus include alginate oligomers with (e.g. containing) 70 to 100% G (guluronate) residues.

Preferably at least 75% or 80%, more particularly at least 85% or 90%, even more particularly at least 91, 92, 93, 94, 95, 96, 97, 98 or 99% of the monomer residues are guluronate. In one embodiment the alginate oligomer may be an oligoguluronate (i.e. a homooligomer of G, or 100% G).

In a further preferred embodiment, the above described alginates of the invention have a primary structure wherein the majority of the G residues are in so called G-blocks. Preferably at least 50%, more preferably at least 70 or 75%, and most preferably at least 80, 85, 90, 92 or 95% of the G residues are in G-blocks. A G-block is a contiguous sequence of at least two G residues, preferably at least 3 contiguous G residues, more preferably at least 4 or 5 contiguous G residues, most preferably at least 7 contiguous G residues.

In particular at least 90% of the G residues are linked 1-4 to another G residue. More particularly at least 95%, more preferably at least 98%, and most preferably at least 99% of the G residues of the alginate are linked 1-4 to another G residue. More specifically at least 70% of the monomer residues in the oligomer are G residues linked 1-4 to another G residue, or more preferably at least 75%, and most preferably at least 80, 85, 90, 92, 93, 94, 95, 96, 97, 98, 99% of the monomers residues of the oligomer are G residues linked 1-4 to another G residue. This 1-4 linkage of two G residues can be alternatively expressed as a guluronic unit bound to an adjacent guluronic unit.

The alginate oligomers of use in the invention are commonly referred to by the skilled person as "high G" or "G-block" oligomers i.e. having a high content of G
residues or G-blocks (e.g. wherein at least 70% of the monomer residues are G, preferably arranged in G-blocks).

The alginate oligomer of use in the invention is preferably a 3- to 35-mer, more preferably a 3- to 28-mer, in particular a 4- to 25-mer, e.g. a 5- to 20-mer, especially a 6- to 22-mer, in particular an 8- to 20-mer, especially a 10- to 15-mer, e.g. having a molecular weight in the range 350 to 6400 Daltons or 350 to 6000 Daltons, preferably 550 to 5500 Daltons, preferably 750 to 5000 Daltons, and especially 750 to 4500 Daltons or 2000 to 3000 Daltons or 900 to 3500 Daltons. Other representative alginate oligomers include, as mentioned above, oligomers with 5, 6, 7, 8, 9, 10, 11, 12 or 13 to 50, 45, 40, 35, 28, 25, 22 or 20 residues.

It may be a single compound or it may be a mixture of compounds, e.g. of a range of degrees of polymerization. As noted above, the monomeric residues in the alginate oligomer, may be the same or different and not all need carry electrically charged groups although it is preferred that the majority (e.g. at least 60%, preferably at least 80% more preferably at least 90%) do. It is preferred that a substantial majority, e.g. at least 80%, more preferably at least 90% of the charged groups have the same polarity. In the alginate oligomer, the ratio of hydroxyl groups to charged groups is preferably at least 2:1, more especially at least 3:1.

The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DP_n), of 3-28, 4-25, 6-22, 8-20 or 10-15, or 5-18 or 7-15 or 8-12, especially 10.

The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DP_n), of 3-24, 4-23, 5-22, 6-21, 7-20, 8-19, 9-18, 10-17, 11-16, 12-15 or 13-14 (e.g. 13 or 14).

The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DP_n), of 4-25, 5-24, 6-23, 7-22, 8-21, 9-20, 10-19, 11-18, 12-17, 13-16, 14-15 (e.g. 14 or 15).

The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DP_n), of 5-26, 6-25, 7-24, 8-23, 9-22, 10-21, 11-20, 12-19, 13-18, 14-17 or 15-16 (e.g. 15 or 16).

The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DP_n), of 4-50, 4-40, 4-35, 4-30, 4-28, 4-26, 4-22, 4-20, 4-18, 4-16 or 4-14.
The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DP), of 5-50, 5-40, 5-25, 5-22, 5-20, 5-18, 5-23, 5-20, 5-18, 5-16 or 5-14.

The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DP), of 6-50, 6-40, 6-35, 6-30, 6-28, 6-26, 6-24, 6-20, 6-19, 6-18, 6-16 or 6-14.

The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DP), of 8-50, 8-40, 8-35, 8-30, 8-28, 8-25, 8-22, 8-20, 8-18, 8-16 or 8-14.

The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DP), of 9-50, 9-40, 9-35, 9-30, 9-28, 9-25, 9-22, 9-20, 9-18, 9-16 or 9-14.

The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DP), of 10-50, 10-40, 10-35, 10-30, 10-28, 10-25, 10-22, 10-20, 10-18, 10-16 or 10-14.

The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DP), of 11-50, 11-40, 11-35, 11-30, 11-28, 11-25, 11-22, 11-20, 11-18, 11-16 or 11-14.

The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DP), of 12-50, 12-40, 12-35, 12-30, 12-28, 12-25, 12-22, 12-20, 12-18, 12-16 or 12-14.

The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DP), of 13-50, 13-40, 13-35, 13-30, 13-28, 13-25, 13-22, 13-20, 13-18, 13-16 or 13-14 (e.g. 13 or 14).

The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DP), of 14-50, 14-40, 14-35, 14-30, 14-28, 14-25, 14-22, 14-20, 14-18, or 14-16.

The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DP), of 15-50, 15-40, 15-35, 15-30, 15-28, 15-25, 15-22, 15-20, or 15-18.

The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DP), of 18-50, 18-40, 18-35, 18-30, 18-28, 18-25, 18-22 or 18-20.

The alginate oligomer of the invention may have a degree of polymerisation (DP), or a number average degree of polymerisation (DPₙ), of 30-100, 30-90, 30-80, 30-75, 30-70, 30-65, 30-60, 30-55, 30-50, 30-45, 30-40 or 30-35.

Preferably the alginate oligomer of the invention is substantially free, preferably essentially free, of alginate oligomers having a degree of polymerisation outside of the ranges disclosed herein. This may be expressed in terms of the molecular weight distribution of the alginate oligomer of the invention, e.g. the percentage of each mole of the alginate oligomer being used in accordance with the invention which has a DP outside the relevant range. The molecular weight distribution is preferably such that no more than 10%, preferably no more than 9, 8, 7, 6, 5, 4, 3, 2, or 1% mole has a DP of three, two or one higher than the relevant upper limit for DPₙ. Likewise it is preferred that no more than 10%, preferably no more than 9, 8, 7, 6, 5, 4, 3, 2, or 1% mole has a DP below a number three, two or one smaller than the relevant lower limit for DPₙ.

Suitable alginate oligomers are described in WO2007/039754, WO2007/039760, WO 2008/125828, and WO2009/068841, the disclosures of which are explicitly incorporated by reference herein in their entirety.

Representative suitable alginate oligomers have a DPₙ in the range 5 to 30, a guluronate fraction (F₇₀) of at least 0.80, a mannuronate fraction (F₅₄) of no more than 0.20, and at least 95 mole% of DP no more than 25.

Further suitable alginate oligomers have a number average degree of polymerization in the range 7 to 15 (preferably 8 to 12), a guluronate fraction (F₇₀) of at least 0.85 (preferably at least 0.90), a mannuronate fraction (F₅₄) of no more than 0.15 (preferably no more than 0.10), and having at least 95% mole with a degree of polymerization less than 17 (preferably less than 14).

Further suitable alginate oligomers have a number average degree of polymerization in the range 5 to 18 (especially 7 to 15), a guluronate fraction (F₇₀) of at least 0.80 (preferably at least 0.85, especially at least 0.92), a mannuronate fraction (F₅₄) of no more than 0.20 (preferably no more than 0.15, especially no more than 0.08), and having at least 95% mole with a degree of polymerization less than 20 (preferably less than 17).
Further suitable alginate oligomers have a number average degree of polymerization in the range 5 to 18, a guluronate fraction ($F_G$) of at least 0.92, a mannuronate fraction ($F_M$) of no more than 0.08, and having at least 95% mole with a degree of polymerization less than 20.

Further suitable alginate oligomers have a number average degree of polymerization in the range 5 to 18 (preferably 7 to 15, more preferably 8 to 12, especially about 10), a guluronate fraction ($F_G$) of at least 0.80 (preferably at least 0.85, more preferably at least 0.90, especially at least 0.92, most especially at least 0.95), a mannuronate fraction ($F_M$) of no more than 0.20 (preferably no more than 0.15, more preferably no more than 0.10, especially no more than 0.08, most especially no more than 0.05), and having at least 95% mole with a degree of polymerization less than 20 (preferably less than 17, more preferably less than 14).

Further suitable alginate oligomers have a number average degree of polymerization in the range 7 to 15 (preferably 8 to 12), a guluronate fraction ($F_G$) of at least 0.92 (preferably at least 0.95), a mannuronate fraction ($F_M$) of no more than 0.08 (preferably no more than 0.05), and having at least 95% mole with a degree of polymerization less than 17 (preferably less than 14).

Further suitable alginate oligomers have a number average degree of polymerization in the range 5 to 18, a guluronate fraction ($F_G$) of at least 0.80, a mannuronate fraction ($F_M$) of no more than 0.20, and having at least 95% mole with a degree of polymerization less than 20.

Further suitable alginate oligomers have a number average degree of polymerization in the range 7 to 15, a guluronate fraction ($F_G$) of at least 0.85, a mannuronate fraction ($F_M$) of no more than 0.15, and having at least 95% mole with a degree of polymerization less than 17.

Further suitable alginate oligomers have a number average degree of polymerization in the range 7 to 15, a guluronate fraction ($F_G$) of at least 0.92, a mannuronate fraction ($F_M$) of no more than 0.08, and having at least 95% mole with a degree of polymerization less than 17.

Further suitable alginate oligomers have a number average degree of polymerization in the range 5 to 20, a guluronate fraction ($F_G$) of at least 0.85 and a mannuronate fraction ($F_M$) of no more than 0.15.

Further suitable alginate oligomers have a number average degree of polymerization in the range 5 to 20, a guluronate fraction ($F_G$) of 0.9-0.95 and a mannuronate fraction ($F_M$) of 0.05-0.1, which may be expressed as an alginate
oligomer having 90-95% G residues and an average molecular weight of 2600 Da. Further suitable alginate oligomers have a number average degree of polymerization about 13 (e.g. 12, 13 or 14), a guluronate fraction \( F_G \) of at least about 0.80, 0.85, 0.87, 0.88, 0.90 or 0.93 (e.g. 0.92, 0.93 or 0.94) and a corresponding mannuronate fraction \( F_M \) of no more than about 0.20, 0.15, 0.13, 0.12, 0.10, or 0.07 (e.g. 0.08, 0.07 or 0.06).

Further suitable alginate oligomers have a number average degree of polymerization about 21 (e.g. 20, 21 or 22), a guluronate fraction \( F_G \) of at least about 0.80 (e.g. 0.85, 0.87, 0.88, 0.90, 0.92, 0.94 or 0.95) and a corresponding mannuronate fraction \( F_M \) of no more than about 0.20 (e.g. 0.15, 0.13, 0.12, 0.10, 0.08, 0.06, 0.05).

Further suitable alginate oligomers have a number average degree of polymerization about 6 (e.g. 5, 6 or 7), a guluronate fraction \( F_G \) of at least about 0.80 (e.g. 0.85, 0.87, 0.88, 0.90, 0.92, 0.94 or 0.95) and a corresponding mannuronate fraction \( F_M \) of no more than about 0.20 (e.g. 0.15, 0.13, 0.12, 0.10, 0.08, 0.06, 0.05).

It will thus be seen that a particular class of alginate oligomers favoured according to the present invention is alginate oligomers defined as so-called "high G" or "G-block" oligomers i.e. having a high content of G residues or G-blocks (e.g. wherein at least 70% of the monomer residues are G, preferably arranged in G-blocks). However, other types of alginate oligomer may also be used, including in particular "high M" or "M-block" oligomers or MG-block oligomers, as described further below. Accordingly, it is alginate oligomers with high proportions of a single monomer type, and with said monomers of this type being present predominantly in contiguous sequences of that monomer type, that represent oligomers that are particularly preferred, e.g. oligomers wherein at least 70% of the monomer residues in the oligomer are G residues linked 1-4 to another G-residue, or more preferably at least 75%, and most preferably at least 80, 85, 90, 92, 93, 94, 95, 96, 97, 98, 99% of the monomers residues of the oligomer are G residues linked 1-4 to another G residue. This 1-4 linkage of two G residues can be alternatively expressed as a guluronic unit bound to an adjacent guluronic unit.

In a further embodiment at least, or more particularly more than, 50% of the monomer residues of the alginate oligomer may be M residues (i.e. mannuronate or mannuronic acid). In other words the alginate oligomer will contain at least or alternatively more than 50% mannuronate (or mannuronic acid) residues. Specific
embodiments thus include alginate oligomers with (e.g. containing) 50 to 70% M (mannuronate) residues or e.g. 70 to 100% M (mannuronate) residues. Further specific embodiments also include oligomers containing 71 to 85% M residues or 85 to 100% M residues. Thus, a representative alginate oligomer for use according to this embodiment of the present invention will contain more than 70% M residues (i.e. more than 70% of the monomer residues of the alginate oligomer will be M residues).

In other embodiments at least 50% or 60%, more particularly at least 70% or 75%, even more particularly at least 80, 85, 90, 95 or 99% of the monomer residues are mannuronate. In one embodiment the alginate oligomer may be an oligomannuronate (i.e. a homooligomer of M, or 100% M).

In a further embodiment, the above described alginites of the invention have a primary structure wherein the majority of the M residues are in so called M-blocks. In this embodiment preferably at least 50%, more preferably at least 70 or 75%, and most preferably at least 80, 85, 90 or 95% of the M residues are in M-blocks. An M block is a contiguous sequence of at least two M residues, preferably at least 3 contiguous M residues, more preferably at least 4 or 5 contiguous M residues, most preferably at least 7 contiguous M residues.

In particular, at least 90% of the M residues are linked 1-4 to another M residue. More particularly at least 95%, more preferably at least 98%, and most preferably at least 99% of the M residues of the alginate are linked 1-4 to another M residue.

Other preferred oligomers are alginate oligomers wherein at least 70% of the monomer residues in the oligomer are M residues linked 1-4 to another M-residue, or more preferably at least 75%, and most preferably at least 80, 85, 90, 92, 93, 94, 95, 96, 97, 98, 99% of the monomers residues of the oligomer are M residues linked 1-4 to another M residue. This 1-4 linkage of two M residues can be alternatively expressed as a mannuronic unit bound to an adjacent mannuronic unit.

In a still further embodiment, the alginate oligomers of the invention comprise a sequence of alternating M and G residues. A sequence of at least three, preferably at least four, alternating M and G residues represents an MG block. Preferably the alginate oligomers of the invention comprise an MG block. Expressed more specifically, an MG block is a sequence of at least three contiguous residues consisting of G and M residues and wherein each non-terminal
(internal) G residue in the contiguous sequence is linked 1-4 and 4-1 to an M residue and each non-terminal (internal) M residue in the contiguous sequence is linked 1-4 and 4-1 to a G residue. Preferably the MG block is at least 5 or 6 contiguous residues, more preferably at least 7 or 8 contiguous residues.

In a further embodiment the minority uronate in the alginate oligomer (i.e. mannanuronate or guluronate) is found predominantly in MG blocks. In this embodiment preferably at least 50%, more preferably at least 70 or 75% and most preferably at least 80, 85, 90 or 95% of the minority uronate monomers in the MG block alginate oligomer are present in MG blocks. In another embodiment the alginate oligomer is arranged such that at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, e.g. 100% of the G and M residues in the oligomer are arranged in MG blocks.

Although at its broadest, the invention extends to embodiments wherein at least 1% but less than 100% of the monomer residues of the oligomer are G residues (i.e. guluronate or guluronic acid), more particularly, and as defined further below, at least 30% of the monomer residues are G residues. Thus, at its broadest the MG block containing alginate oligomer may contain at least 1%, but less than 100%, guluronate (or guluronic acid) residues, but generally the MG block containing alginate oligomer will contain at least 30% (or at least 35, 40 or 45% or 50% G) but less than 100% G. Specific embodiments thus include MG block containing alginate oligomers with (e.g. containing) 1 to 30% G (guluronate) residues, 30 to 70% G (guluronate) residues or 70 to 99% G (guluronate) residues. Thus, a representative MG block containing alginate oligomer for use according to the present invention may contain more than 30%, but less than 70%, G residues (i.e. more than 30%, but less than 70%, of the monomer residues of the MG block alginate oligomer will be G residues).

Preferably more than 30%, more particularly more than 35% or 40%, even more particularly more than 45, 50, 55, 60 or 65%, but in each case less than 70%, of the monomer residues of the MG block containing alginate oligomer are guluronate. Alternatively, less than 70%, more preferably less than 65% or 60%, even more preferably less than 55, 50, 45, 40 or 35%, but in each case more than 30% of the monomer residues of the MG block containing alginate oligomer are guluronate. Any range formed by any combination of these values may be chosen. Therefore for instance the MG block containing alginate oligomer can have e.g. between 35% and 65%, 40% and 60% or 45% and 55% G residues.
In another embodiment the MG block containing alginate oligomer may have approximately equal amounts of G and M residues (e.g. ratios between 65% G/35% M and 35% G/65% M, for instance 60% G/40% M and 40% G/60% M; 55% G/45% M and 45% G/55% M; 53% G/47% M and 47% G/53% M; 51% G/49% M and 49% G/51% M; e.g. about 50% G and about 50% M) and these residues are arranged predominantly, preferably entirely or as completely as possible, in an alternating MG pattern (e.g. at least 50% or at least 60, 70, 80, 85, 90 or 95% or 100% of the M and G residues are in an alternating MG sequence).

In certain embodiments the terminal uronic acid residues of the oligomers of use in the invention do not have a double bond, especially a double bond situated between the C4 and C5 atom. Such oligomers may be described as having saturated terminal uronic acid residues. The skilled man would be able to prepare oligomers with saturated terminal uronic acid residues without undue burden. This may be through the use of production techniques which yield such oligomers, or by converting (saturating) oligomers produced by processes that yield oligomers with unsaturated terminal uronic acid residues.

The alginate oligomer will typically carry a charge and so counter ions for the alginate oligomer may be any physiologically tolerable ion, especially those commonly used for charged drug substances, e.g. sodium, potassium, ammonium, chloride, mesylate, meglumine, etc. Ions which promote alginate gelation e.g. group 2 metal ions may also be used.

While the alginate oligomer may be a synthetic material generated from the polymerisation of appropriate numbers of guluronate and mannuronate residues, the alginate oligomers of use in the invention may conveniently be obtained, produced or derived from natural sources such as those mentioned above, namely natural alginate source materials.

Polysaccharide to oligosaccharide cleavage to produce the alginate oligomer useable according to the present invention may be performed using conventional polysaccharide lysis techniques such as enzymatic digestion and acid hydrolysis. In one favoured embodiment acid hydrolysis is used to prepare the alginate oligomers on the invention. In other embodiments enzymatic digestion is used with an additional processing step(s) to saturate the terminal uronic acids in the oligomers.

Oligomers may then be separated from the polysaccharide breakdown products chromatographically using an ion exchange resin or by fractionated
precipitation or solubilisation or filtration. US 6,121,441 and WO 2008/125828, which are explicitly incorporated by reference herein in their entirety, describe a process suitable for preparing the alginate oligomers of use in the invention. Further information and discussion can be found in for example in "Handbooks of Hydrocolloids", Ed. Phillips and Williams, CRC, Boca Raton, Florida, USA, 2000, which textbook is explicitly incorporated by reference herein in its entirety.

The alginate oligomers may also be chemically modified, including but not limited to modification to add charged groups (such as carboxylated or carboxymethylated glycans) and alginate oligomers modified to alter flexibility (e.g. by periodate oxidation).

Alginate oligomers (for example oligoguluronic acids) suitable for use according to the invention may conveniently be produced by acid hydrolysis of alginic acid from, but not limited to, Laminaria hyperbora and Lessonia nigrescens, dissolution at neutral pH, addition of mineral acid reduce the pH to 3.4 to precipitate the alginate oligomer (oligoguluronic acid), washing with weak acid, resuspension at neutral pH and freeze drying.

The alginates for production of alginate oligomers of the invention can also be obtained directly from suitable bacterial sources e.g. Pseudomonas aeruginosa or Azotobacter vinelandii.

In embodiments where alginate oligomers which have primary structures in which the majority of the G residues are arranged in G-blocks rather than as single residues are required, algal sources are expected to be most suitable on account of the fact that the alginates produced in these organisms tend to have these structures. The bacterial sources may be more suitable for obtaining alginate oligomers of different structures.


The G content of alginates (for example an algal source material) can be increased by epimerisation, for example with mannuronan C-5 epimerases from A. vinelandii or other epimerase enzymes. Thus, for example in vitro epimerisation
may be carried out with isolated epimerases from *Pseudomonas* or *Azotobacter*, e.g. AlgG from *Pseudomonas fluorescens* or *Azotobacter vinelandii* or the AlgE enzymes (AlgE1 to AlgE7) from *Azotobacter vinelandii*. The use of epimerases from other organisms that have the capability of producing alginate, particularly algae, is also specifically contemplated. The *in vitro* epimerisation of low G alginates with *Azotobacter vinelandii* AlgE epimerases is described in detail in Ertesvag *et al.* (supra) and Strugala *et al.* (Gums and Stabilisers for the Food Industry, 2004, 12, The Royal Society of Chemistry, 84 - 94).

To obtain G-block containing alginates or alginate oligomers, epimerisation with one or more *Azotobacter vinelandii* AlgE epimerases other than AlgE4 is preferred as these enzymes are capable of producing G block structures. On the other hand AlgE4 epimerase can be used to create alginates or alginate oligomers with alternating stretches of M/G sequence or primary structures containing single G residue as it has been found that this enzyme seems preferentially to epimerise individual M residues so as to produce single G residues linked to M residues rather than producing G blocks. Particular primary structures can be obtained by using different combinations of these enzymes.

Mutated versions of these enzymes or homologues from other organisms are also specifically contemplated as of use. WO 94/09124 describes recombinant or modified mannuronan C-5 epimerase enzymes (AlgE enzymes) for example encoded by epimerase sequences in which the DNA sequences encoding the different domains or modules of the epimerases have been shuffled or deleted and recombined. Alternatively, mutants of naturally occurring epimerase enzymes, (AlgG or AlgE) may be used, obtained for example by site directed or random mutagenesis of the AlgG or AlgE genes.

A different approach is to create *Pseudomonas* and *Azotobacter* organisms that are mutated in some or all of their epimerase genes in such a way that those mutants produce alginates of the required structure for subsequent alginate oligomer production, or even alginate oligomers of the required structure and size (or molecular weight). The generation of a number of *Pseudomonas fluorescens* organisms with mutated AlgG genes is described in detail in WO 2004/01 1628 and Gimmestad, M., *et al.*, 2003 (supra). The generation of a number of *Azotobacter vinelandii* organisms with mutated AlgE genes is disclosed in Gimmestad, M., *et al.*, 2006 (supra).
A further approach is to delete or inactivate the endogenous epimerase genes from an Azotobacter or a Pseudomonas organism and then to introduce one or more exogenous epimerase genes, which may or may not be mutated (i.e. may be wild-type or modified) and the expression of which may be controlled, for example by the use of inducible or other "controllable promoters". By selecting appropriate combinations of genes, alginates of predetermined primary structure can be produced.

A still further approach would be to introduce some or all of the alginate biosynthesis machinery of Pseudomonas and/or Azotobacter into a non-alginate producing organism (e.g. E. coli) and to induce the production of alginate from these genetically modified organisms.

When these culture-based systems are used, the primary structure of the alginate or alginate oligomer products can be influenced by the culture conditions. It is well within the capabilities of the skilled man to adjust culture parameters such as temperature, osmolarity, nutrient levels/sources and atmospheric parameters in order to manipulate the primary structure of the alginates produced by a particular organism.

References to "G residues/G" and "M residues/M" or to guluronic acid or mannuronic acid, or guluronate or mannuronate are to be read interchangeably as references to guluronic acid/guluronate and mannuronic acid/mannuronate (specifically α-L-guluronic acid/guluronate and β-D-mannuronic acid/mannuronate), and further include derivatives thereof in which one or more available side chains or groups have been modified without resulting in a capacity to widen the spectrum of bacitracin's therapeutically useful activity against bacteria species to include Gram negative bacteria which is substantially lower than that of the unmodified oligomer. Common saccharide modifying groups would include acetyl, sulphate, amino, deoxy, alcohol, aldehyde, ketone, ester and anhydro groups. The alginate oligomers may also be chemically modified to add charged groups (such as carboxylated or carboxymethylated glycans), and to alter flexibility (e.g. by periodate oxidation). The skilled man would be aware of still further chemical modifications that can be made to the monosaccharide subunits of oligosaccharides and these can be applied to the alginate oligomers of use in the invention.

The direct covalent bond between the alginate oligomer and the bacitracin-class antibiotic is a covalent bond formed by an atom of the alginate oligomer and an atom of the bacitracin-class antibiotic. The atoms contributing to the bond may
together or independently be carbon, oxygen, sulphur, nitrogen and/or phosphorous. The bond may be single, double or triple. In certain embodiments the bond is part of an organic functional group. The skilled person would be entirely familiar with the options available for suitable organic functional groups which could act as linkers between the alginate oligomer and the bacitracin-class antibiotics. Non-limiting examples thereof may include ester, carbonate ester, orthoester, ketone, ketal, hemiketal, ketene, ether, acetal, hemiacetal, peroxo, methylenedioxy, carbamate, amide, amine, amine oxide, hydroxamic acid, imine, imide, imidate, azide, azo, oxime, carboximide, carbazone, hydrozone, sulfide, disulfide, sulfinyl, sulfonyl, carbonothioyl, thioamide, thiocarbamide, thioketone, thioketal, sulphonate ester, dithiocarbamate, semicarbazone, phosphine or phosphodiester functional groups. As shown in the Examples, the formation of amide and ester bonds may be convenient and advantageous.

The covalent molecular linker may be any molecule, typically an organic molecule, or part thereof, which has a structure formed from covalently bonded atoms which is capable of bonding covalently with an alginate oligomer and a bacitracin-class antibiotic. Within the conjugate there will be a continuous series of covalently bonded atoms from the alginate oligomer to bacitracin-class antibiotic via the molecular linker. In preferred embodiments at least one of the covalent bonds in said series is as defined above. The molecular linker may however further comprise non-covalent, e.g. ionic bonds, in parts of the molecule which are not contributing to the covalent linkage between the bacitracin-class antibiotic and the alginate oligomer.

The covalent molecular linker may be linear, circular or branched. In certain embodiments the molecular linker will have a molecular weight of equal to or less than 1500 Daltons, e.g. equal to or less than 1250, 1000, 900, 800, 700, 600, 500, 400, 300, 200 or 100 Daltons.

In certain embodiments at least one direct covalent bond between the alginate oligomer and the covalent molecular linker is as defined above. In certain embodiments at least one direct covalent bond between the bacitracin-class antibiotic and the covalent molecular linker is as defined above. Each bond may be the same or different. The covalent linker molecule may comprise at least one covalent bond as defined above, preferably in the part of that molecule which contributes to the continuous series of covalently bonded atoms from the alginate oligomer to bacitracin-class antibiotic via the molecular linker.
The covalent molecular linker may be or comprise an amino acid or a peptide, e.g. of equal to or fewer than 15 amino acid residues, e.g. of equal to or fewer than 12, 10, 8, 6, 5, 4, 3 or 2 amino acid residues. The amino acid may be and the peptide may comprise any of the amino acids described above. Specific examples of peptide linkers which may be used include but are not limited to peptides of Gly and/or Ser residues (e.g. (Gly)\textsubscript{2-8}, (Ser)\textsubscript{2-8}, (GGGGS)\textsubscript{1-3}, (EAAAK)\textsubscript{1-3}, A(EAAAK)\textsubscript{1-3}A; Leu-Glu; (Xaa-Pro)\textsubscript{1-6} (e.g. (Glu-Pro)\textsubscript{1-6}, (Lys-Pro)\textsubscript{1-6}, (Ala-Pro)\textsubscript{1-6}; VSQTS KLTR\textsubscript{1}AETVF PDV (Factor Xla/Factor Vila sensitive cleavage); PLGJ.LWA (matrix metalloprotease-1 sensitive cleavage); RVLJ.AEA (HIV-1 protease sensitive cleavage; EDVVCcjSMSY (NS3 protease sensitive cleavage; GGIEGRJ.GS (Factor Xa sensitive cleavage); TRHRQPRJ.GWE (furin sensitive cleavage); AGNRVRRJ.SVG (furin sensitive cleavage); GFLG\textsubscript{1} (Cathepsin B sensitive cleavage).

The covalent molecular linker may be or comprise a monosaccharide or an oligosaccharide other than guluronate or mannuronate or a polymer formed therefrom, e.g. a saccharide of equal to or fewer than 12 amino acid residues, e.g. equal to or fewer than 10, 8, 6, 5, 4, 3 or 2 amino acid residues. Thus the covalent molecular linker may be a monosaccharide, disaccharide or trisaccharide or sugar derivatives thereof such as aldonic and uronic acids, deoxy or amino sugars, sulfated sugars, and sugar alcohols. The monosaccharide or one or more of the monosaccharide residues of the disaccharide or trisaccharide may be a triose, a tetrose, a pentose, a hexose, a heptose, an octose, a nonose or a decose in pyranose or furanose form and/or L- or D- form where appropriate and/or sugar derivatives thereof. Pentose or hexose saccharides/residues are preferred, e.g. mannose (e.g. D-mannose), galactose (e.g. D-galactose), glucose (e.g. D-glucose), fructose, fucose (e.g. L-fucose), N-acetyl-glucosamine, N-acetylglactosamine, rhamnose, galactosamine, glucosamine (e.g. D-glucosamine), galacturonic acid, glucuronic acid, N-acetylneuraminic acid, methyl D-mannopyranoside (mannoside), a-methyl-glucoside, galactoside, ribose, xylose, arabinose, saccharate, mannitol, sorbitol, inositol, glycerol and derivatives of these monomers. The disaccharide may be exemplified by acarviosin, allolactose, cellobiose, chitobiose, galactose-alpha-1,3-galactose, dentiobiose, isomaltoolose, isomaltose, isomaltulose, kojibiose, lactitol, lactobionic acid, lactose, lactulose, laminaribiose, maltotol, maltose, mannotriose, melibiose, melibiole, neohesperidose, nigerose, robinose, rutinose, sambubiose, sophorose, sucralfate,
sucralose, sucrose, sucrose acetate isobutyrate, sucrose octaacetate, trehalose, truranose, xylobiose or derivatives of these disaccharides.

The covalent molecular linker may be or comprise a nucleotide or an oligonucleotide, i.e. a nucleic acid, e.g. a ribonucleotide or a deoxyribonucleotide.

The linker may also be or comprise a straight chain, branched or cyclic, substituted or unsubstituted, alkyl, alkenyl or alkylnl group (typically C₂ to C₈) or derivative thereof such as aminohexanoic acid or one of a range of commercially available PEG (polyethylene glycol) linkers.

Further examples of suitable covalent linker molecules include but are not limited to acetyl, succinyl, aconityl (c/s or trans), glutaryl, methylsuccinyl, trimellityl cysteamine, penicillamine, N-(2-mercaptopropionyl)glycine, 2-mercaptopropionic acid, homocysteine, 3-mercaptopropionic acid and deamino-penicillamine groups.

In certain embodiments the covalent linker molecule may be a plurality of the molecules and/or groups described above.

In certain embodiments the direct covalent bond or the covalent linker molecule (more specifically a covalent bond within the linker molecule, a covalent bond between the linker molecule the alginate oligomer and/or a covalent bond between and the linker molecule and the bacitracin-class antibiotic) is selected for its ability to be lysed under conditions representative, or advantageously essentially unique to, a target site or location within a subject, e.g. conditions representative of a bacterial infection, the respiratory tract (especially the lower respiratory tract including the lungs, more particularly the lungs of a patient with cystic fibrosis) or wounds (in particular chronic wounds). In this way delivery of the bacitracin-class antibiotic may be made more selective for the target site.

In specific embodiments a covalent bond, a functional group containing said covalent bond or linker molecule may be selected which is sensitive to (labile at, degrades at, lyases at) a pH which is lower than normal physiological pH (pH 7.2), i.e. acidic pH, e.g. a pH of from about 3 to about 7, 6.5, 6, 5.5, 5, 4.5, 4, or 3.5. Sites or locations of inflammation, especially inflammation caused by infection typically have a pH in these ranges. Functional groups including esters, cis-aconityl, disulphides and hydrozones may be sensitive to lower pHs, i.e. may be described as acid labile.

In specific embodiments a covalent bond, functional group or linker molecule may be selected which is sensitive to reactive oxygen species. Sites or locations of inflammation, especially inflammation caused by infection typically have
high levels of reactive oxygen species. Functional groups including thioketals and thioethers may be sensitive to reactive oxygen species.

In further specific embodiments a covalent bond, functional group or linker molecule may be selected which is lysed by enzymes produced or secreted only at the target site or overproduced or oversecreted at the target site. This may include enzymes such as glycosidases, nucleases and peptidases, in particular those secreted by infecting bacteria and those secreted by inflammatory cells of the host, e.g. lysozyme, alginate lyase, DNasel, restriction endonucleases, neutrophil elastase, cathepsins, phospholipases and β-lactamases. It may however be advantageous to choose a covalent bond, functional group or linker molecule which is not lysed by enzymes capable of degrading the alginate oligomer or the bacitracin-class antibiotic and as such separation of the alginate oligomer from the bacitracin-class antibiotic will occur separately to the degradation of the alginate oligomer or bacitracin-class antibiotic.

In other embodiments the direct covalent bond or the covalent linker molecule may be selected for its stability under conditions representative, of advantageously essentially unique to, a target site or location within a subject, e.g. the location described above or locations or sites the conjugate may encounter en route to those locations and sites following administration and/or which the conjugate may encounter during its bodily distribution. An amide bond, a thioether bond or a Gly-Gly peptide linker may be, for example, suitable here.

In preferred embodiments the bacitracin-alginate oligomer conjugate consists of at least one alginate oligomer covalently bonded to a bacitracin-class antibiotic via an amide bond formed from a carboxyl group on the alginate and an amine group on the bacitracin molecule. Preferably the bacitracin-class antibiotic is selected from bacitracin A1, A2, B1, B2, B3, C, D1, D2, D3 and E and, more preferably, from bacitracin A (A1 and/or A2) and bacitracin B (B1 and/or B2). The alginate oligomer will preferably contain 2 to 100 monomer residues. The alginate oligomer may also have at least 70% G residues.

In preferred embodiments the bacitracin-alginate oligomer conjugate consists of at least one alginate oligomer covalently bonded to a bacitracin-class antibiotic via an ester bond formed from a carboxyl group on the alginate and hydroxyl group on the bacitracin molecule. Preferably the bacitracin-class antibiotic is selected from bacitracin A1, A2, B1, B2, B3, C, D1, D2, D3 and E and, more preferably, from bacitracin A (A1 and/or A2) and bacitracin B (B1 and/or B2).
The alginate oligomer will preferably contain 2 to 100 monomer residues. The alginate oligomer may also have at least 70% G residues.

Multivalent arrangements are contemplated in which more than one alginate oligomer is covalently linked to the bacitracin-class antibiotic. The alginate oligomers may be the same or different and may be linked to the bacitracin-class antibiotic via the same type of covalent bond or covalent molecular linker. In other arrangements an alginate oligomer may be covalently linked to a plurality of bacitracin molecules in the manner described herein. The bacitracin molecules may be the same or different and may or may not be covalently linked to other alginate oligomers.

References to the bacitracin-alginate oligomer conjugates of the invention extends to pharmaceutically acceptable salts, solvates or hydrates thereof, diastereoisomers, tautomers, enantiomers, and active metabolites thereof. Suitable salts include acid addition salts from inorganic acids such as hydrochloric, sulphuric, phosphoric, nitric, carbonic, boric, sulfamic, and hydrobromic acids, or salts of pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, citric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulphonic, toluenesulphonic, benzenesulphonic, salicylic, sulphanilic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic, ascorbic, fendizoic, 4-4’-methylenebis-3-hydroxy-2-naphthoic acid, o-(p-hydroxybenzoyl)benzoic, 4-4’-dihydroxytriphenylmethane-2-carboxylic acid and valeric acids. Base salts include, but are not limited to, those formed with pharmaceutically acceptable cations, such as sodium, potassium, lithium, calcium, magnesium, ammonium and alkylammonium.

In a further aspect the invention provides a method for the preparation of a bacitracin-alginate oligomer conjugate of the invention, said method comprising

(i) providing an alginate oligomer and a bacitracin-class antibiotic and forming a direct covalent bond between two molecular groups thereon; or

(ii) providing an alginate oligomer, a bacitracin-class antibiotic and a covalent molecular linker and forming a direct covalent bond between two molecular groups on the alginate oligomer and the linker molecule and forming a direct covalent bond between two molecular groups on the bacitracin-class antibiotic and the linker molecule; or
providing an alginate oligomer and a bacitracin-class antibiotic wherein one or both carry a covalent molecular linker molecule covalently bonded thereto and covalently linking the alginate oligomer to the bacitracin-class antibiotic via at least one of the linker molecules; and optionally

(ii) separating at least a portion of the bacitracin-alginate oligomer conjugate from the reaction mixture.

In certain embodiments the invention provides a method for the preparation of a bacitracin-alginate oligomer conjugate of the invention, said method comprising

(i) providing an aqueous solution of an alginate oligomer having an available carboxyl group;

(ii) contacting said alginate solution with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDO) in an amount and under conditions sufficient to activate at least one carboxyl group in the alginate oligomer;

(iii) optionally contacting said carboxyl activated alginate oligomer with sulfo N-hydroxysuccinimide (sulfo-NHS) in an amount and under conditions sufficient to form an amine-reactive sulfo-NHS ester;

(iv) contacting said carboxyl activated alginate oligomer of step (ii) or the amine-reactive sulfo-NHS ester of step (iii) with a bacitracin-class antibiotic having an available primary amine group in an amount and under conditions sufficient to form an amide bond between the alginate oligomer and the bacitracin-class antibiotic; and

(v) separating at least a portion of the bacitracin-alginate oligomer conjugate from the reaction mixture.

In certain embodiments the invention provides a method for the preparation of a bacitracin-alginate oligomer conjugate of the invention, said method comprising

(i) providing a solution of an alginate oligomer having an available carboxyl group, preferable an organic (e.g. DMF and/or DMSO) solution;

(ii) contacting said alginate solution with dicyclohexylcarbodiimide (DCC) in an amount and under conditions sufficient to form an O-acylisourea intermediate;
(iii) contacting said O-acylisourea intermediate with an bacitracin-class antibiotic having an available hydroxyl group and 4-N,N-dimethylaminopyridine (DMAP) in amounts and under conditions sufficient to form an ester bond between the alginate oligomer and the bacitracin-class antibiotic; and

(iv) separating at least a portion of the bacitracin-alginate oligomer conjugate from the reaction mixture;

wherein steps (ii) and (iii) may be performed simultaneously.

As mentioned above and as shown in the Examples, bacitracin-alginate oligomer conjugates are a class of novel chemical entities having therapeutically useful antibacterial efficacy against both Gram negative and Gram positive bacteria, i.e. a spectrum of therapeutically useful activity which is wider than non-conjugated bacitracin-class antibiotics. This makes possible the effective treatment of bacterial infections (including Gram negative infections).

Thus, in a further aspect the invention provides a pharmaceutical composition comprising a bacitracin-alginate oligomer conjugate as defined herein and a pharmaceutically acceptable excipient, carrier or diluent. Suitable excipients, carriers or diluents are described and specific pharmaceutical compositions are detailed below.

The invention further relates to the use of the bacitracin-alginate oligomer conjugates as described herein and the pharmaceutical compositions comprising the same in the combat of bacterial infection, in particular Gram negative bacterial infection. The term "combat" as used herein includes both therapy and prophylaxis (i.e. the treatment or prevention of a bacterial infection).

Thus in this aspect the invention provides the bacitracin-alginate oligomer conjugates of the invention as described herein and pharmaceutical compositions comprising them for use in therapy, particularly for use in the treatment or prevention of a bacterial infection, preferably a Gram negative bacterial infection.

Specifically, in a further aspect the invention provides a method for the treatment or prevention of a bacterial infection, preferably a Gram negative bacterial infection, in a subject with, suspected to have, or at risk of, a bacterial infection, said method comprising administering to said subject an effective amount of a bacitracin-alginate oligomer conjugate of the invention as defined herein.
The invention further provides a bacitracin-alginate oligomer conjugate of the invention as defined herein, for use in the treatment or prevention of a bacterial infection, preferably a Gram negative bacterial infection, in a subject with, suspected to have, or at risk of, a bacterial infection.

An "effective", more particularly a "pharmaceutically effective", amount of the bacitracin-alginate oligomer conjugate is that amount of conjugate that provides a measurable treatment or prevention of the target bacterial infection, e.g. a Gram negative bacterial infection.

In the above described embodiments the primary physiological result to be achieved is the contact of the site of infection (in particular the bacteria which are present in the infected site or location, and which may include multiple sites or locations of infection in the body, including also a systemic infection) and/or a site (e.g. a surface) at which the infection may occur (or is at risk of occurring) with the bacitracin-alginate oligomer conjugate.

Expressed alternatively the invention further provides the use of an a bacitracin-alginate oligomer conjugate of the invention as defined herein for the manufacture of a medicament for use in the treatment or prevention of a bacterial infection, preferably a Gram negative bacterial infection, in a subject with, suspected to have, or at risk of, a bacterial infection.

The term "bacterial infection" (or "infected by" or "infected with" and the like) is used broadly herein to indicate that the subject may comprise, or contain, or carry, the bacteria in question, i.e. that the bacteria may simply be present in or on the subject, and this may include any site or location in or on the body of the subject. It is not necessary that the infection of the subject be manifest as a clinical disease (i.e. that the infection result in clinical symptoms in the subject), although this is of course encompassed. A subject who is suspected to be infected or who is at risk of infection may be a subject who has been exposed to the bacteria or to an infected subject, or a subject presenting with clinical signs or symptoms of infection (in the case of a suspected infection), or a subject who is susceptible to infection, whether generally (e.g. due to the clinical status of the subject) or particularly to the bacteria in question.

Also in accordance with certain aspects of the invention there may be a preceding step of identifying a subject as being a subject with, suspected to have, or at risk of, a bacterial infection, or a step of diagnosing a subject as a subject with, suspected to have, or at risk of, a bacterial infection. In particular, the bacterial
infection may be of a type which is known to be untreatable, or at least difficult to treat, in usual clinical practice with a bacitracin-class antibiotic. In one embodiment the bacteria are identified as or suspected to be bacteria which are unresponsive to (i.e. sensitive to) a bacitracin-class antibiotic, at least at therapeutic doses. In certain embodiments the sensitivity/resistance of that infection (or more particularly the bacteria within the infection) to a bacitracin-class antibiotic may be determined.

Alternatively or in addition to the above described preceding step, in accordance with the invention there may be a following step in which the subject's clinical indicators of the bacterial infection are assessed and preferably compared to a corresponding assessment made prior to, or earlier in, said treatment in order to determine any changes therein.

The diagnosis and monitoring of bacterial infections based on readily observable physiological indicators is entirely routine for clinicians. Molecular biological and microbiological methods may also be used to more confirm diagnoses and to provide more information on the causative agents, e.g. taxonomic information, possible indications of virulence and their sensitivity to antibiotics.

The invention encompasses the use of a single bacitracin-alginate oligomer conjugate or a mixture (multiplicity/plurality; two or more) of different bacitracin-alginate oligomer conjugates. Such mixtures may comprise conjugates carrying different bacitracin-class antibiotics and the same alginate oligomer. Such mixtures may comprise conjugates carrying the same bacitracin-class antibiotic and different alginate oligomers. Such mixtures may comprise conjugates carrying different bacitracin-class antibiotics and different alginate oligomers.

The bacterial infection targeted according to the invention may comprise bacteria from any genera or species of bacteria. Examples of genera or species of bacteria include, but are not limited to, Abiotrophia, Achromobacter, Acidaminococcus, Acidovorax, Acinetobacter, Actinobacillus, Actinobaculum, Actinomadura, Actinomyces, Aerococcus, Aeromonas, Afipia, Agrobacterium, Alcaligenes, Alloccoccus, Alteromonas, Amycolata, Amycolatopsis, Anaerobe-spirillum, Anaerorhabdus, Arachnia, Arcanobacterium, Arcobacter, Arthrobacter, Atopobium, Aureobacterium, Bacteroides, Balneatrix, Bartonella, Bergeyella, Bifidobacterium, Bilophila Brachmamella, Borrelia, Bordetella, Brachyspira, Brevibacillus, Brevibacterium, Brevundimonas, Brucella, Burkholderia, Buttiauxella, Butyrivibrio, Calymmatobacterium, Campylobacter, Capnocytophaga, Cardiobacterium, Catonella, Cedecea, Cellulomonas, Centipeda, Chlamydia,

Preferably the bacterial infection targeted according to the invention comprises bacteria selected from the following genera: Achromobacter, Acinetobacter, Actinobacillus, Aeromonas, Agrobacterium, Alcaligenes, Alteromonas, Bacteroides, Bartonella, Borrelia, Bordetella, Brucella, Burkholderia, Campylobacter, Cardiobacterium, Chlamydia, Chlamydophila, Chromobacterium, Chyseobacterium, Clostridium, Ctritroacter, Comamonas, Corynebacterium, Coxiella, Cryptobacterium, Edwardsiella, Eikenella, Enterobacter, Enterococcus, Erwinia, Kingella, Klebsiella, Lactobacillus, Lactococcus, Legionella, Leptospira, Leptotrichia, Listeria, Listonella, Mobiluncus, Moraxella, Morganella, Mycobacterium, Mycoplasma, Neisseria, Nocardia, Nocardiosis, Pantoea, Parachlamydia, Pasteurella, Peptococcus, Peptostreptococcus, Prevotella, Propionibacterium, Proteus, Providencia, Pseudomonas, Ralstonia, Rickettsia, Salmonella, Shewenella, Shigella, Sphingobacterium, Sphingomonas, Staphylococcus, Stenotrophomonas, Streptobacillus, Streptococcus, Streptomyces, Treponem and Yersinia.

Thus, the invention may be used against Gram positive or Gram negative bacteria, or indeed Gram-indeterminate bacteria, but use against Gram-negative bacteria, for instance those particularised above, is preferred. These would include bacteria from the genera or species Achromobacter, Acidaminococcus, Acidovorax, Acinetobacter, Actinobacillus, Aeromonas, Afipia, Agrobacterium, Alcaligenes, Alteromonas, Anaerobospiillum, Anaerorhabdus, Arcobacter, Bacteroides, Balneatrix, Bartonella, Bergeyella, Bilophila, Branhamella, Borrelia, Bordetella, Brachyspira, Brevibacillus, Brevundimonas, Brucella, Burkholderia, Buttiauxella, Calymmatobacterium, Campylobacter, Capnocytophaga, Cardiobacterium,

Preferably the Gram negative bacterium targeted according to the invention is selected from the following genera: Achromobacter, Acinetobacter, Actinobacillus, Aeromonas, Agrobacterium, Alcaligenes, Alteromonas, Bacteroides, Bartonella, Borrelia, Bordetella, Brucella, Burkholderia, Campylobacter, Cardiobacterium, Chlamydia, Chlamydophila, Chromobacterium, Chyseobacterium, Chryseomonas, Citrobacter, Comamonas, Coxiella, Edwardsiella, Eikenella, Enterobacter, Erwinia, Kingella, Klebsiella, Legionella, Leptospira, Leptotrichia,
Listonella, Moraxella, Morganella, Mycoplasma, Neisseria, Pantoea, Parachlamydia, Pasteurella, Prevotella, Proteus, Providencia, Pseudomonas, Ralstonia, Rickettsia, Salmonella, Shigella, Sphingobacterium, Sphingomonas, Stenotrophomonas, Streptobacillus, Treponem and Yersinia.

Within the Gram-negative bacteria the Enterobacteriaceae and the Gram-negative bacteria non-fermenting bacteria are of particular note.

Enterobacteriaceae include, but are not limited to, bacteria from the genera Alisheawanella, Alterococcus, Aquamonas, Aranicola, Azotivirga, Brenneria, Budvicia, Buttiauxella, Cedecea, Citrobacter, Cronobacter, Dickeya, Edwardsiella, Enterobacter, Erwinia, Escherichia, Ewingella, Grimontella, Hafnia, Klebsiella, Kluyvera, Leclercia, Leminorella, Moellerella, Morganella, Obesumbacterium, Pantoea, Pectobacterium, Phlomobacter, Photobacter, Plesiomonas, Pragia, Proteus, Providencia, Rahnella, Raoultella, Salmonella, Samsonia, Serratia, Shigella, Sodalis, Tatumella, Trabulsiella, Wigglesworthia, Xenorhabdus, Yersinia, Yokenella. Preferred genera of Enterobacteriaceae include Escherichia, Klebsiella, Salmonella, Shigella, Yersinia and Providencia.

Non-fermenting Gram-negative bacteria include, but are not limited to, bacteria from the genera Pseudomonas, Acinetobacter, Stenotrophomonas and Burkholderia, Achromobacter, Algaligenes, Bordetella, Brevundimonas, Comamonas, Elizabethkingia (formerly Chryseobacterium), Methylobacterium, Moraxella, Ochrobactrum, Oligella, Psychrobacter, Ralstonia, Roseomonas, Shewanella, Sphingobacterium, e.g. Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, and Burkholderia spp..

Preferably the bacteria may be selected from the genera Pseudomonas, Acinetobacter, Stenotrophomonas, Burkholderia, Escherichia, Klebsiella, Providencia, e.g. Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, Burkholderia spp, E. coli, Klebsiella pneumoniae and Burkholderia cepacia, Burkholderia mallei, Burkholderia pseudomallei, Acinetobacter Iwoffi, Providencia stuartii, Providencia rettgeri, Providencia alcalifaciens, Klebsiella oxytoca, Pseudomonas anguilliseptica, Pseudomonas oryzihabitans, Pseudomonas plecoglossicida and Pseudomonas luteola. More preferably the bacteria may be selected from the genera Pseudomonas, Acinetobacter, Escherichia and Klebsiella, e.g. Pseudomonas aeruginosa, Acinetobacter baumannii, E. coli, and Klebsiella pneumoniae.
In certain aspects, the infection is a nosocomial infection, an infection in the respiratory tract of patients, e.g. in patients suffering from cystic fibrosis, chronic obstructive pulmonary disease, congestive obstructive airway disease / congestive obstructive airway pneumonia (COAD/COAP), pneumonia, emphysema, bronchitis or sinusitis; an infection in a wound, particularly a chronic wound (including burns), a device related infection associated with implantable or prosthetic medical devices e.g. prosthetic valve endocarditis or an infection of a line or a catheter or an artificial joints or a tissue replacements or an endotracheal or tracheotomy tube. Examples of the types of bacteria which commonly cause such infections include

_Pseudomonas aeruginosa_, **Acinetobacter baumannii**, _Stenotrophomonas maltophilia_, _Burkholderia spp_ (e.g. _B. cepacia_), _E. coli_, _Klebsiella pneumoniae_, _Staphylococcus aureus_, Methicillin Resistant _Staphylococcus aureus_ (MRSA), _Clostridium difficile_, _Mycobacterium tuberculosis_, _Enterococcus and Vancomycin-Resistant Enterococcus and Providencia stuartii_. Other infections of importance in accordance with the invention include infections by _Bartonella hensela_, mycobacteria (e.g. _Mycobacterium avium_ Complex (MAC), _M. kansasii_, _M. marinum_, _M. ulcerans_, _M. xenopi_), Haemophilus influenzae type b (Hib) or _Legionella_ (e.g. _Legionella pneumophila_; Legionnaire’s disease), leprosy (_M. leprae_), human granulocytic anaplasmosis (_Anaplasma phagocytophilum_), brucellosis (_Brucella melitensis_), meningococcal disease (_Neisseria meningitides_) and anthrax (_Bacillus anthracis_).

The bacteria may be multidrug resistant, e.g. bacteria which are resistant to antibiotics from at least 3, or at least 4, 5, 6, 7, 8, 9 or 10 antibiotic classes, e.g. the aminoglycosides (e.g. amikacin, gentamicin, kanamycin, capreomycin, neomycin, netilmicin, streptomycin, tobramycin); the β-lactams (e.g. the carbecephems (e.g. loracarbef); the 1st generation cephalosporins (e.g. cefadroxil, cefazolin, cephalexin); 2nd generation cephalosporins (e.g. cefaclor, cefamandole, cephalexin, cefoxitin, cefprozil, cefuroxime); 3rd generation cephalosporins (e.g. cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, cefetizoxime, ceftriaxone); 4th generation cephalosporins (e.g. cefepime); the monobactams (e.g. aztreonam)); the macrolides (e.g. azithromycin, clarithromycin, dirithromycin, erythromycin, troleandomycin); the monobactams (e.g. aztreonam); the penicillins (e.g. amoxicillin, ampicillin, carbenicillin, cloxacillin, dicloxacillin, nafcillin, oxacillin, penicillin G, penicillin V, piperacillin, ticarcillin); the polypeptide antibiotics (e.g. bacitracin, colistin and polymyxin B, but in certain
embodiments not bacitracin); the quinolones (e.g. ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, trovafloxacin); the sulfonamides (e.g. mafenide, sulfacetamide, sulfamethizole, sulfasalazine, sulfisoxazole, trimethoprim- sulfamethoxazole); the tetracyclines (e.g. demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline); the glyyclcyclines (e.g. tigecycline); the carbapenems (e.g. imipenem, meropenem, ertapenem, doripenem, panipenem/betamipron, biapenem, PZ-601); and other antibiotics including chloramphenicol; clindamycin, ethambutol; fosfomycin; isoniazid; linezolid; metronidazole; nitrofurantoin; pyrazinamide; quinupristin/dalfopristin; spectinomycin; fosfomycin and vancomycin.

Susceptibility, that is sensitivity, (and conversely resistance and tolerance) to an antibiotic can be measured in any convenient way, e.g. with dilution susceptibility tests and/or disk diffusion tests. Preferably the susceptibility of a bacterial strain to an antibiotic is expressed in terms of the Minimum Inhibitory Concentration (MIC) of that antibiotic for that microorganism (Jorgensen et al., Manual of Clinical Microbiology, 7th ed. Washington, D.C: American Society for Microbiology, 1999; 1526-43), i.e. that concentration of antibiotic that completely inhibits growth of that bacterial strain.

The skilled man would appreciate that the extent of the difference in tolerance/susceptibility sufficient to constitute resistance will vary depending on the antibiotic and bacterial strain under test and the test used. Many regulatory bodies, e.g. the European Committee on Antimicrobial Susceptibility Testing (EUCAST) set so called "breakpoints" for specific antimicrobials and microorganisms which are discriminatory antimicrobial concentrations used in the interpretation of results of susceptibility testing to define isolates as susceptible, intermediate or resistant to the antimicrobial agent under test. The skilled person can utilise such information to ascertain whether or not the bacterial infection being treated by the invention is resistant to the antibiotic in question under these definitions.

In certain embodiments the target infection will be bacteria in a biofilm. However, in other embodiments the bacterium will not be in a biofilm. (e.g. will be growing planktonically). Put differently, the bacterium will be, or will not be, in a biofilm mode of growth; or will be, or will not be, in a non-biofilm mode of growth.

By "biofilm" it is meant a community of microorganisms characterized by a predominance of sessile cells that are attached to a substratum or interface or to each other (some motile cells may also be present) and that are embedded in a
matrix of extracellular polymers (more specifically extracellular polymers that they have produced) characterised in that the microorganisms of this colony exhibit an altered phenotype with respect to growth rate and gene transcription (for example as compared to their "non-biofilm" or free-floating or planktonic counterparts). By "in a biofilm" it is meant that the bacterium targeted by the method of the invention is within (completely or in part), on or associated with the polymer matrix of a biofilm. Viewed differently, bacteria that are "not in a biofilm" are organisms that are either in isolation, e.g. planktonic, or if in an aggregation of a plurality of organisms, that aggregation is unorganised and/or is devoid of the matrix characteristic of a biofilm. In each case, the individual bacteria do not exhibit an altered phenotype that is observed in their biofilm dwelling counterparts.

In certain embodiments the bacterial infection does not contain bacteria from the genus Acinetobacter. In certain embodiments the bacterial infection to be treated or prevented in accordance with the invention does not contain bacteria which are multidrug resistant.

In particular embodiments the invention may provide for the treatment or prevention of respiratory infections or conditions associated therewith (e.g. cystic fibrosis, pneumonia, COPD, COAD, COAP, bronchitis, sinusitis, an infection in a chronic wound (including burns), a device related infection associated with implantable or prosthetic medical devices, bacteraemia, septicaemia, septic shock, or sepsis.

In one preferred embodiment the bacterial infection is a respiratory infection in a subject suffering from an underlying respiratory disorder or condition, including notably CF, COPD/COAD, or asthma.

"Treatment" when used in relation to the treatment of a bacterial infection/medical condition in a subject in accordance with the invention is used broadly herein to include any therapeutic effect, i.e. any beneficial effect in relation to the infection or on the condition. Thus, not only included is eradication or elimination of the infection, or cure of the subject or infection, but also an improvement in the infection or condition of the subject. Thus included for example, is an improvement in any symptom or sign of the infection or condition, or in any clinically accepted indicator of the infection/condition (for example a decrease in wound size or an acceleration of healing time). Treatment thus includes both curative and palliative therapy, e.g. of a pre-existing or diagnosed infection/condition, i.e. a reactionary treatment.
"Prevention" as used herein refers to any prophylactic or preventative effect. It thus includes delaying, limiting, reducing or preventing the infection/condition or the onset of the infection/condition, or one or more symptoms or indications thereof, for example relative to the infection/condition or symptom or indication prior to the prophylactic treatment. Prophylaxis thus explicitly includes both absolute prevention of occurrence or development of the infection/condition, or symptom or indication thereof, and any delay in the onset or development of the infection/condition or symptom or indication thereof, or reduction or limitation of the development or progression of the infection/condition or symptom or indication thereof.

The subject may be any human or non-human animal subject, but more particularly may be a human or a non-human vertebrate, e.g. a non-human mammal, bird, amphibian, fish or reptile. In a preferred embodiment the subject is a mammalian subject. The animal may be a livestock or a domestic animal or an animal of commercial value, including laboratory animals or an animal in a zoo or game park. Representative animals therefore include dogs, cats, rabbits, mice, guinea pigs, hamsters, horses, pigs, sheep, goats and cows. Veterinary uses of the invention are thus covered. The subject may be viewed as a patient. Preferably the subject is a human. In some embodiments the subject is not a ruminant mammal.

The term "in a subject" is used broadly herein to include sites or locations inside a subject or on a subject, e.g. an external body surface, and may include in particular infection of a medical device e.g. an implanted or "in-dwelling" medical device. The term "in a patient" should be interpreted consistently with this.

The location of the infection may therefore be a surface in the oral cavity (e.g. teeth, gingiva, gingival crevice, periodontal pocket), the reproductive tract (e.g. cervix, uterus, fallopian tubes), the peritoneum, middle ear, prostate, the urinary tract, vascular intima, the eye, i.e. ocular tissue (e.g. the conjunctiva, corneal tissue, lachrymal duct, lachrymal gland, eyelid) the respiratory tract, lung tissue (e.g. bronchial and alveolial), heart valves, the gastrointestinal tract, skin, scalp, nails and the interior of wounds, particularly chronic wounds and surgical wounds, which may be topical or internal wounds. Other surfaces include the exterior of organs, particularly those undergoing transplantation, for example, heart, lungs, kidney, liver, heart valve, pancreas, intestine, corneal tissue, arterial and venous grafts and skin.
The infection may therefore also be present in body fluids (e.g. blood, plasma, serum, cerebrospinal fluid, GI tract contents, semen, sputum and other pulmonary secretions) and tissues (e.g. adrenal, hepatic, renal, pancreatic, pituitary, thyroid, immune, ovarian, testicular, prostate, endometrial, ocular, mammary, adipose, epithelial, endothelial, neural, muscle, pulmonary, epidermis, osseous).

The infection may further be found on any "in-dwelling" medical or surgical equipment or devices. This may include any kind of line, including catheters (e.g. central venous and urinary catheters), prosthetic devices e.g., heart valves, artificial joints, false teeth, dental crowns, dental caps and soft tissue implants (e.g. breast, buttock and lip implants). Any kind of implantable medical device is included (e.g. stents, intrauterine devices, pacemakers, intubation tubes (e.g. endotracheal or tracheostomy tubes), prostheses or prosthetic devices, lines or catheters). An "in-dwelling" medical device may include a device in which any part of it is contained within the body, i.e. the device may be wholly or partly in-dwelling.

The infection may be acute, or alternatively chronic, e.g. an infection that has persisted for at least 5 or at least 10 days, particularly at least 20 days, more particularly at least 30 days, most particularly at least 40 days.

A bacterial infection can occur in any subject but some subjects will be more susceptible to infection that others. Subjects who are susceptible to bacterial infection include, but are not limited to, subjects whose epithelial and/or endothelial barrier is weakened or compromised, subjects whose secretion-based defences to microbial infection have been abrogated, disrupted, weakened or undermined, and subjects who are immunocompromised, immunodeficient or immunosuppressed (i.e. a subject in whom any part of the immune system is not working normally, or is working sub-normally, in other words in whom any part of the immune response, or an immune activity is reduced or impaired, whether due to disease or clinical intervention or other treatment, or in any way).

Representative examples of subjects who are susceptible to bacterial infection include, but are not limited to, subjects with a pre-established infection (e.g. with bacteria, viruses, fungi or parasites such as protozoa), especially subjects with HIV, subjects with bacteraemia, sepsis and subjects with septic shock; subjects with immunodeficiency, e.g. subjects preparing for, undergoing or recovering from chemotherapy and/or radiotherapy, organ (e.g. bone marrow, liver, lung, heart, heart valve, kidney, etc.) transplant subjects (including autograft,
allograft and xenograft patients); subjects with AIDS; subjects resident in a healthcare institution, e.g. hospital, especially subjects in intensive care or critical care (i.e. those units concerned with the provision of life support or organ support systems to patients); subjects on respiratory ventilators; subjects suffering from trauma; subjects with burns, subjects with acute and/or chronic wounds; neonatal subjects; elderly subjects; subjects with cancer (defined broadly herein to include any neoplastic condition; malignant or non-malignant), especially those with cancers of the immune system (e.g. leukaemias, lymphomas and other haematological cancers); subjects suffering from auto-immune conditions such as rheumatoid arthritis, diabetes mellitus type I. Crohn’s disease, especially those undergoing immunosuppression treatment for those diseases; subjects with reduced or abrogated epithelial or endothelial secretion (e.g. mucous, tears, saliva) and/or secretion clearance (e.g. subjects with poorly functioning cilia on mucosal tissue and/or patients with hyperviscous mucous (e.g. smokers and subjects with COPD, COAD, COAP, bronchitis, cystic fibrosis, emphysema, lung cancer, asthma, pneumonia or sinusitis)) and subjects fitted with a medical device.

The bacitracin-alginate oligomer conjugates of the invention may be administered to the subject in any convenient form or by any convenient means in order to deliver effective amounts to the bacteria of the target infection and/or to the site carrying the invention or the site at risk of infection, e.g. by topical, enteral (e.g. oral, buccal, sublingual, rectal), parenteral (e.g. intravenous, intraspinal, intramuscular, subcutaneous), routes or by inhalation (including nasal inhalation). Administration may achieve systemic distribution or localised distribution, by which it is meant that delivery is effected to the bacteria of the target infection and/or to the site carrying the infection or to the site at risk of infection, but essentially no other location in the patient. The skilled person would be able to select an appropriate administration means to suit any particular target infection and/or site carrying the infection or site at risk of infection. Localised administration, particularly achieved by topical administration, may be preferred.

The skilled man will be able to formulate the bacitracin-alginate oligomer conjugates of the invention into pharmaceutical compositions that are adapted for these routes of administration and body distribution according to any of the conventional methods known in the art and widely described in the literature.

More specifically, the bacitracin-alginate oligomer conjugates of the invention may be incorporated, optionally together with other active agents, with
one or more conventional carriers, diluents and/or excipients, to produce
conventional galenic preparations such as tablets, pills, granules (e.g. in free form
or enclosed in capsules), powders (e.g. inhalable powders, including dry inhalable
powders), lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions,
syrups, aerosols (as a solid or in a liquid medium), sprays (e.g. nasal sprays),
compositions for use in nebulisers, ointments, creams, salves, soft and hard
gelatine capsules, suppositories, pessaries, sterile injectable solutions, sterile
packaged powders, and the like. Enteric coated solid or liquid compositions, e.g.
enteric coated tablets and enteric coated granules (which may be provided in an
enteric-coated capsule or in a non-enteric-coated capsule i.e. in which the coating
may or may not be an enteric coating); sterile inhalable and sterile injectable
compositions are of particular note.

Examples of suitable carriers, excipients, and diluents are lactose, dextrose,
sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, inert alginate
polymers, tragacanth, gelatine, calcium silicate, microcrystalline cellulose,
polyvinylpyrrolidone, cellulose, water syrup, water, water/ethanol, water/ glycol,
water/polyethylene, hypertonic salt water, glycol, propylene glycol, methyl cellulose,
methylhydroxybenzoates, propyl hydroxybenzoates, talc, magnesium stearate,
mineral oil or fatty substances such as hard fat or suitable mixtures thereof.
Excipients and diluents of note are mannitol and hypertonic salt water (saline).

The compositions may additionally include lubricating agents, wetting
agents, emulsifying agents, suspending agents, preserving agents, sweetening
agents, flavouring agents, and the like.

For topical administration the bacitracin-alginate oligomer conjugates can be
incorporated into creams, ointments, gels, salves, transdermal patches and the like.
Further topical systems that are envisaged to be suitable are in situ drug delivery
systems, for example gels where solid, semi-solid, amorphous or liquid crystalline
gel matrices are formed in situ and which may comprise the alginate oligomer
(which may be any alginate oligomer as herein defined). Such matrices can
conveniently be designed to control the release of the bacitracin-alginate oligomer
conjugates from the matrix, e.g. release can be delayed and/or sustained over a
chosen period of time. Such systems may form gels only upon contact with
biological tissues or fluids, e.g. mucosal surfaces. Typically the gels are
bioadhesive and/or mucoadhesive. Delivery to any body site that can retain or be
adapted to retain the pre-gel composition can be targeted by such a delivery
technique. Such systems are described in WO 2005/023176, which is explicitly incorporated by reference herein in its entirety.

Parenterally administrable forms, e.g. solutions suitable for delivery intravenously, should be sterile and free from physiologically unacceptable agents, and should have low osmolarity to minimize irritation or other adverse effects upon administration and thus solutions should preferably be isotonic or slightly hypertonic, e.g. hypertonic salt water (saline). Suitable vehicles include aqueous vehicles customarily used for administering parenteral solutions such as sterile water for injection, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection and other solutions such as are described in Remington’s Pharmaceutical Sciences, 15th ed., Easton: Mack Publishing Co., pp. 1405-1412 and 1461-1487 (1975) and The National Formulary XIV, 14th ed. Washington: American Pharmaceutical Association (1975), which is explicitly incorporated by reference herein in its entirety. The solutions can contain preservatives, antimicrobial agents, buffers and antioxidants conventionally used for parenteral solutions, excipients and other additives which are compatible with the bacitracin-alginate oligomer conjugates and which will not interfere with the manufacture, storage or use of products.

Simple sterile solutions of bacitracin-alginate oligomer conjugates or simple sterile liquid compositions comprising bacitracin-alginate oligomer conjugates may be especially convenient for use during surgical procedures and for delivery to the lungs, e.g. by nebuliser, or to the paranasal sinuses, e.g. by a nasal spray device.

Solid or liquid formulations of the bacitracin-alginate oligomer conjugates may be provided with an enteric coating that prevents degradation in the stomach and/or other parts of the upper GI tract but permits degradation in the lower GI tract, e.g. the small intestine. Such coatings are routinely prepared from polymers including fatty acids, waxes, shellac, plastics, and plant fibres. Specific examples thereof include but are not limited to methyl acrylate-methacrylic acid copolymers, methyl methacrylate-methacrylic acid copolymers, cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate (hypromellose acetate succinate), polyvinyl acetate phthalate (PVAP), cellulose acetate trimellitate, and sodium alginate polymer. Enteric coated tablets and enteric coated granules (which may be provided in an enteric-coated capsule or in a non-enteric coated capsule) are of particular note. Enteric coated granules may be prepared in accordance with the teachings of WO 1989008448 and Al-
Khedairy, E.B.H, 2006, Iraqi J.Pharm.Sci., Vol.15 (1) 49, the contents of which are incorporated herein by reference, although the skilled person would be aware of further alternative techniques which may be used.

The relative content of the bacitracin-alginate oligomer conjugates in the compositions of the invention can vary depending on the dosage required and the dosage regime being followed but will be sufficient to achieve an effective amount at the target treatment site, i.e. the bacteria of the target infection and/or the site carrying the infection, or the site at risk of infection, taking account of variables such as the physical size of the subject to be treated, the nature of the subject's particular ailments, and the location and identity of the target treatment area. The skilled man would know that the amounts of the bacitracin-alginate oligomer conjugates can be reduced if a multiple dosing regime is followed or increased to minimise the number of administrations or applications.

A representative topical formulation, e.g. a cream, ointment or salve, which may be used to administer a bacitracin-alginate oligomer conjugate of the invention to the skin or cervix or other parts of the lower female reproductive system might contain 1 to 25%, 1 to 20%, 1 to 15%, 1 to 10%, 1 to 9%, 1 to 8%, 1 to 7%, 1 to 6%, 5 to 25%, 5 to 20%, 5 to 15%, 5 to 10%, 5 to 9%, 5 to 8%, 5 to 7%, 5 to 6%, 8 to 25%, 8 to 20%, 8 to 15%, 8 to 10%, 9 to 25%, 9 to 20%, or 9 to 15% w/v of the bacitracin-alginate oligomer conjugate, the remainder being comprised of pharmaceutically acceptable excipients, and/or other active agents if being used. Delivery devices designed for the application of topical formulations to the female reproductive system are known and may be employed to deliver the above mentioned formulations if convenient.

A pessary may be used to administer a bacitracin-alginate oligomer conjugate of the invention to the lower parts of the female reproductive tract. A representative formulation may contain 1 to 25%, 1 to 20%, e.g. 1 to 15%, 1 to 10%, 1 to 9%, 1 to 8%, 1 to 7%, 1 to 6%, 5 to 25%, 5 to 20%, 5 to 15%, 5 to 10%, 5 to 9%, 5 to 8%, 5 to 7%, 5 to 6%, 8 to 25%, 8 to 20%, 8 to 15%, 8 to 10%, 9 to 25%, 9 to 20%, or 9 to 15% w/v or w/w of the bacitracin-alginate oligomer conjugate, the remainder being comprised of pharmaceutically acceptable excipients, including solid excipients, and/or other active agents if being used. Rectal suppositories may be formulated similarly.

For administration to the nose or paranasal sinuses a sterile aqueous and/or oil-based liquid formulation (e.g. an emulsion) may be used; administered for
instance by a nasal spray device, e.g. propellant-free or propellant-assisted. A representative formulation may contain 1 to 25%, 1 to 20%, e.g. 1 to 15%, 1 to 10%, 1 to 9%, 1 to 8%, 1 to 7% or 1 to 6%, 5 to 25%, 5 to 20%, 5 to 15%, 5 to 10%, 5 to 9%, 5 to 8%, 5 to 7%, 5 to 6%, 8 to 25%, 8 to 20%, 8 to 15%, 8 to 10%, 9 to 25%, 9 to 20%, or 9 to 15% w/v or w/w of the bacitracin-alginate oligomer conjugate, the remainder being comprised of pharmaceutically acceptable excipients, e.g. water, and/or other active agents if being used.

A representative inhalable solution to be used to administer a bacitracin-alginate oligomer conjugate of the invention to the upper respiratory tract typically will be sterile and may contain 6 to 25%, e.g. 6 to 20%, 6 to 15%, 6 to 10%, 8 to 25%, 8 to 20%, 8 to 15 %, 9 to 25%, 9 to 20%, 9 to 15 %, 10 to 15%, 10 to 20%, 10 to 25%, 15 to 20% or 15 to 25% w/v of the bacitracin-alginate oligomer conjugate, the remainder being comprised of pharmaceutically acceptable excipients, e.g. water, and/or other active agents if being used.

A representative inhalable powder to be used to administer a bacitracin-alginate oligomer conjugates of the invention to the lower respiratory tract may contain up to 90%, e.g. up to 85%, 80%, 75% or 70%, e.g. 50 to 90%, 55 to 90%, 60 to 90%, 65 to 90%, 70 to 90%, 75 to 90%, 80 to 90%, 85 to 90%, 50 to 85%, 55 to 85%, 60 to 85%, 65 to 85%, 70 to 85%, 75 to 85%, 80 to 85%, 50 to 80%, 55 to 80%, 60 to 80%, 65 to 80%, 70 to 80%, 75 to 80%, 50 to 70%, 55 to 70%, 60 to 70%, or 65 to 70% w/v or w/w of the bacitracin-alginate oligomer conjugate, the remainder being comprised of pharmaceutically acceptable excipients and/or other active agents if being used in the same composition.

In other embodiments a slow, delayed or sustained release formulations may be used for delivery, e.g. to the nose or paranasal sinuses. A representative formulation may be a powder containing the bacitracin-alginate oligomer conjugate or a suspension of said powder, said powder containing up to 90%, e.g. up to 85%, 80%, 75% or 70%, e.g. 50 to 90%, 55 to 90%, 60 to 90%, 65 to 90%, 70 to 90%, 75 to 90%, 80 to 90%, 85 to 90%, 50 to 85%, 55 to 85%, 60 to 85%, 65 to 85%, 70 to 85%, 75 to 85%, 80 to 85%, 50 to 80%, 55 to 80%, 60 to 80%, 65 to 80%, 70 to 80%, 75 to 80%, 50 to 70%, 55 to 70%, 60 to 70%, or 65 to 70% w/v or w/w of the bacitracin-alginate oligomer conjugate, the remainder being comprised of pharmaceutically acceptable excipients and/or other active agents if being used. The powder may comprise a coating that controls release of the bacitracin-alginate oligomer conjugate.
A representative tablet to be used to administer a bacitracin-alginate oligomer conjugate of the invention to the lower GI tract may contain up to 99%, up to 95%, 90%, 85% or 80%, e.g. 50 to 95%, 55 to 95%, 60 to 95%, 65 to 95%, 70 to 95%, 75 to 95%, 80 to 95%, 85 to 95%, 90 to 95%, 50 to 90%, 55 to 90%, 60 to 90%, 65 to 90%, 70 to 90%, 75 to 90%, 80 to 90%, 85 to 90%, 50 to 90%, 55 to 85%, 60 to 80% or, 65 to 75% w/v or w/w of the bacitracin-alginate oligomer conjugate, the remainder being comprised of pharmaceutically acceptable excipients and/or other active agents if being used. The tablet may be a multi-layered tablet.

An enteric coated tablet may also be effective in administering a bacitracin-alginate oligomer conjugate of the invention to the lower GI tract. A representative enteric coated tablet may contain up to 95%, e.g. up to 90%, 85% or 80%, e.g. 55 to 90%, 60 to 90%, 65 to 90%, 70 to 90%, 75 to 90%, 80 to 90%, 85 to 90%, 55 to 85%, 60 to 85%, 65 to 85%, 70 to 85%, 75 to 85%, 80 to 85%, 50 to 80%, 55 to 80%, 60 to 80%, 65 to 80%, 70 to 80%, or 75 to 80% w/v or w/w of the bacitracin-alginate oligomer conjugate, the remainder being comprised of pharmaceutically acceptable excipients, including the enteric coating (e.g. polymers including fatty acids, waxes, shellac, plastics, and plant fibres) and/or other active agents if being used. The tablet may be a multi-layered tablet, e.g. as described above.

Enteric coated granules may also be effective in administering a bacitracin-alginate oligomer conjugate of the invention to the lower GI tract. Such granules may be provided in a capsule which itself may or may not be provided with an enteric coating. A representative enteric coated granule may contain up to 95%, e.g. up to 90%, 85% or 80%, e.g. 55 to 90%, 60 to 90%, 65 to 90%, 70 to 90%, 75 to 90%, 80 to 90%, 85 to 90%, 55 to 85%, 60 to 85%, 65 to 85%, 70 to 85%, 75 to 85%, 80 to 85%, 50 to 80%, 55 to 80%, 60 to 80%, 65 to 80%, 70 to 80%, 75 to 80%, or 75 to 80% w/v or w/w of the bacitracin-alginate oligomer conjugate, the remainder being comprised of pharmaceutically acceptable excipients, including the enteric coating (e.g. polymers including fatty acids, waxes, shellac, plastics, and plant fibres) and/or other active agents if being used.

A representative aqueous solution for delivery of the bacitracin-alginate oligomer conjugate of the invention by injection (e.g. by intravenous, intraspinal, intramuscular or subcutaneous injection) will be sterile and may contain 6 to 25%, e.g. 6 to 20%, 6 to 15%, 6 to 10%, 8 to 25%, 8 to 20%, 8 to 15 %, 9 to 25%, 9 to 20%, 9 to 15 %, 10 to 15%, 10 to 20%, 10 to 25%, 15 to 20%, or 15 to 25% w/v of
the bacitracin-alginate oligomer conjugate, the remainder being comprised of water and pharmaceutically acceptable excipients and/or other active agents if being used.

The bacitracin-alginate oligomer conjugates may be used at a daily dose of 0.1 g to 10 g, e.g. 0.5 g to 5 g, 0.8 g to 3 g, 1 g to 2 g, e.g. about 2 g, which may be administered at one or more times per day (e.g. bis daily) and in one or more dosage forms or administration events (e.g. two tablets bis daily).

The bacitracin-alginate oligomer conjugates as defined herein may be used in conjunction or combination with one or more further therapeutically active agents, which may include other anti-microbial (e.g. antibacterial, antibiotic, antifungal and antiviral) agents, immunostimulatory agents, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), bronchodilators, mucus viscosity-reducing agents (i.e. an agent which reduces the viscosity of mucus and which terms are used interchangeably with the term "mucolytic agent") or CFTR modulators (also known as "CFTR modifiers").

The further agent, e.g. antibiotic, may be unconjugated to an alginate oligomer or to any other conjugating moiety.

The bacitracin-alginate oligomer conjugate and the further therapeutically active agent may, for example, be administered together, in a single pharmaceutical formulation or composition, or separately (i.e. separate, sequential or simultaneous administration). Thus, bacitracin-alginate oligomer conjugate and the further therapeutically active agent may be combined, e.g. in a pharmaceutical kit or as a combined ("combination") product.

Thus a further aspect of the invention provides a product (e.g. a pharmaceutical combination or a kit) comprising a bacitracin-alginate oligomer conjugate as defined herein together with a further therapeutically active agent (e.g. those described above) as combined preparation for separate, sequential or simultaneous use in treating or preventing a bacterial infection, preferably a Gram negative bacterial infection, in a subject.

More generally this aspect of the invention also provides a kit comprising a bacitracin-alginate oligomer conjugate as defined herein together with a further therapeutically active agent (e.g. those described above).

Combinations comprising a bacitracin-alginate oligomer conjugate as herein defined and an antibiotic, an antifungal, a CFTR modulator and/or a mucus viscosity reducing agent are especially preferred. Such pharmaceutical products
and pharmaceutical compositions are preferably adapted for use in the medical methods of the invention.

The further therapeutically active agent may conveniently be applied before, simultaneously with or following the bacitracin-alginate oligomer conjugate. Conveniently the further therapeutically active agent is applied at substantially the same time as the bacitracin-alginate oligomer conjugate or afterwards. In other embodiments the further therapeutically active agent may conveniently be applied or administered before the bacitracin-alginate oligomer conjugate. The further therapeutically active agent can also be given (e.g. administered or delivered) repeatedly at time points appropriate for the agent used. The skilled person is able to devise a suitable dosage regimen. In long term treatments the bacitracin-alginate oligomer conjugate can also be used repeatedly. The bacitracin-alginate oligomer conjugate can be applied as frequently as the further therapeutically active agent, or more or less frequently. The frequency required may depend on the site or location in or on the patient to which the bacitracin-alginate oligomer conjugate is administered and also the overall nature of the clinical condition displayed by the particular patient undergoing treatment.

The bacitracin-alginate oligomer conjugate and the further therapeutically active agent may therefore be formulated together or separately, that is in the same or in different formulations or pharmaceutical compositions, and may be provided for administration by the same or different routes. The use of bacitracin-alginate oligomer conjugate as herein defined to manufacture such pharmaceutical products and pharmaceutical compositions for use in the medical methods of the invention is also contemplated.

Representative antibiotics which may be used in conjunction or combination with the bacitracin-alginate oligomer conjugates as defined herein include, but are not limited to, the aminoglycosides (e.g. amikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin); the β-lactams (e.g. the carbecephems (e.g. loracarbef); the 1st generation cephalosporins (e.g. cefadroxil, cefazolin, cephalaxin); 2nd generation cephalosporins (e.g. cefaclor, cefamandole, cephalaxin, cefoxitin, cefprozil, cefuroxime); 3rd generation cephalosporins (e.g. cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone); 4th generation cephalosporins (e.g. cefepime); the monobactams (e.g. aztreonam); the macrolides (e.g. azithromycin, clarithromycin, dirithromycin, erythromycin, troleandomycin); the monobactams
(e.g. aztreonam); the penicillins (e.g. amoxicillin, ampicillin, carbenicillin, cloxacillin, dicloxacillin, nafcillin, oxacillin, penicillin G, penicillin V, piperacillin, ticarcillin); the polypeptide antibiotics (e.g. colistin, polymyxin B, but in certain embodiments not bacitracin); the quinolones (e.g. ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, trovafloxacin); the sulfonamides (e.g. mafenide, sulfacetamide, sulfamethizole, sulfasalazine, sulfisoxazole, trimethoprim-sulfamethoxazole); the tetracyclines (e.g. demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline); the glycyclines (e.g. tigecycline); the carbapenems (e.g. imipenem, meropenem, ertapenem, doripenem, panipenem/betamipron, biapenem, PZ-601); other antibiotics include chloramphenicol; clindamycin, ethambutol; fosfomycin; isoniazid; linezolid; metronidazole; nitrofurantoin; pyrazinamide; quinupristin/dalfopristin; rifampin; spectinomycin; and vancomycin.

Representative antifungals include, but are not limited to the polyenes (e.g. natamycin, rimocidin, filipin, nystatin, amphotericin B, candidin; the imidazoles (e.g. miconazole, ketoconazole, clotrimazole, econazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole); the triazoles (e.g. fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, terconazole); the allylamines (e.g. terbinafine, amorolfine, naftifine, butenafine); and the echinocandins (e.g. anidulafungin, caspofungin, micafungin).

Representative antivirals include, but are not limited to abacavir, acyclovir, adefovir, amantadine, amprenavir, arbidol, atazanavir, atripla, boceprevir, cidofovir, combivir, darunavir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, fomivirsen, fosamprenavir, foscarnet, fosfonet, ganciclovir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, interferon type III, interferon type II, interferon type I, lamivudine, lopinavir, loviride, maraviroc, moroxydine, nelfinavir, nevirapine, nexavir, oseltamivir, penciclovir, peramivir, pleconaril, podophyllotoxin, raltegravir, ribavirin, rimantadine, ritonavir, saquinavir, stavudine, tenofovir, tenofovir disoproxil, tipranavir, trifluridine, trizivir, tromantadine, truvada, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine, zalcitabine, zanamivir, and zidovudine.

Representative immunostimulatory agents include, but are not limited to, cytokines e.g. TNF, IL-1, IL-6, IL-8 and immunostimulatory alginates, such as high M-content alginates as described for example in US 5,169,840, WO91/1205 and
WO03/045402 which are explicitly incorporated by reference herein in their entirety, but including any alginate with immunostimulatory properties.

Representative examples of suitable corticosteroids include but are not limited to prednisone, flunisolide, triamcinolone, fluticasone, budesonide, mometasone, beclomethasone, amcinonide, budesonide, desonide, fluocinonide, fluocinolone, halcinonide, hydrocortisone, cortisone, tixocortol, prednisolone, methylprednisolone, prednisone, betamethasone, dexamethasone, fluocortolone, aclometasone, prednicarbate, clobetasol, clobetasol, and fluprednidene.

Representative NSAIDs include, but are not limited to, the salicylates (e.g. aspirin (acetylsalicylic acid), choline magnesium trisalicylate, diflunisal, salsalate, the propionic acid derivatives (e.g. ibuprofen, dexibuprofen, dexketoprofen, fenoprofen, flurbiprofen, ketoprofen, loxoprofen, naproxen, oxaprozin), the acetic acid derivatives (e.g. aceclofenac, diclofenac, etodolac, indomethacin, ketorolac, nabumetone, tolmetin, sulindac), the enolic acid derivatives (e.g. droxicam, isoxicam, lornoxicam, meloxicam, piroxicam, tenoxicam), the anthranilic acid derivatives (e.g. flufenamic acid, meclofenamic acid, mafenamic acid, tolfenamic acid) and the selective COX-2 inhibitors (Coxibs; e.g. celecoxib, etoricoxib, lumiracoxib, parecoxib, rofecoxib, valdecoxib). The propionic acid derivatives (e.g. ibuprofen, dexibuprofen, dexketoprofen, fenoprofen, flurbiprofen, ketoprofen, loxoprofen, naproxen, oxaprozin) are preferred, ibuprofen being most preferred.

Representative examples of suitable bronchodilators include but are not limited to the β2 agonists (e.g. the short-acting β2 agonists (e.g. pirbuterol, epinephrine, salbutamol, levosalbutamol, clenbuterol, terbutaline, procaterol, metaproterenol, fenoterol, bitolterol mesylate, ritodrine, isoprenaline); the long-acting β2 agonists (e.g. salmeterol, formoterol, bambuterol, clenbuterol); and the ultra-long-acting β2 agonists (e.g. indacaterol)), the anticholinergics (e.g. ipratropium, oxitropium, tiotropium) and theophylline.

As used herein, the terms "mucolytic agent" and "mucus viscosity reducing agent" are intended to encompass agents which reduce the intrinsic viscosity of mucus and agents which reduce the attachment of mucus to underlying epithelium, in particular agents which directly or indirectly disrupt the molecular interactions within or between the components of mucus, agents which affect the hydration of mucus and agents which modulate the ionic microenvironment of the mucosal epithelium (particularly the levels of divalent cations, e.g. calcium). Representative examples of suitable mucus viscosity reducing agents include, but are not limited
to, a nucleic acid cleaving enzyme (e.g. a DNase such as DNase I or dornase alfa), hypertonic saline, gelsolin, a thiol reducing agent, an acetylcysteine, an uncharged low molecular weight polysaccharide (e.g. dextran, mannitol), arginine (or other nitric oxide precursors or synthesis stimulators), an agonist of the P2Y2 subtype of purinergic receptors (e.g. denfosol) or an anionic polyamino acid (e.g. poly ASP or poly GLU). Ambroxol, bromhexine, carboxisteine, domiodol, eprazinone, erdosteine, letosteine, mesna, sobrerol, stepronin, tiopronin are specific mucolytics of note. DNase I and hypertonic saline are preferred.

CFTR modulators are small molecules which can redress, at least partially, a CFTR dysfunction. Present CFTR modulators fall into three main groups: CFTR potentiators, CFTR correctors and read-through agents (Derichs, N., Eur. Respir. Rev., 2013, 22(127), 58-65; Petit, R.S. and Fellner, C., Pharmacy and Therapeutics, 2014, 39(7), 500-511; the contents of which are incorporated herein by reference). CFTR potentiators are CFTR modulators which increase the activity of the CFTR ion channel present on the epithelial cell surface. CFTR correctors are CFTR modulators which increase the amount of CFTR protein delivered or retained at the epithelial cell surface. Read-through agents (also known as "premature stop codon suppressors" (PSC suppressors) or "premature termination codon suppressors" (PTC suppressors, which terms are used interchangeably herein) are CFTR modulators which cause the translation machinery of the cell to pass over any premature termination codon in the CFTR mRNA thereby increasing the amount of substantially full length and functional CFTR produced.

Representative examples of suitable CFTR potentiators include, but are not limited to, ivacaftor (VX-770; N-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide) and VRT-532 (4-methyl-2-(5-phenyl-1 H-pyrazol-3-yl)-phenol) of Vertex Pharmaceuticals™.

Representative examples of suitable CFTR correctors include, but are not limited to, Prototypical lumacaftor (VX-809) and VX-661 of Vertex Pharmaceuticals™ and N6022 (3-[1-(4-carbamoyl-2-methylphenyl)-5-(4-imidazol-1-ylphenyl)]pyrrol-2-yl]propanoic acid).

Representative examples of suitable read-through agents include, but are not limited to, ataluren (PTC124) of PTC Therapeutics and gentamicin.

The invention will be further described with reference to the following non-limiting Examples.
EXAMPLES

Example 1 - Preparation of bacitracin-alginate oligomer conjugates

Preparation of alginate oligomers by acid hydrolysis

Sodium alginate, containing >60% guluronate monomers (PRONOVA UP MVG), was dissolved in dH$_2$O (10 mg/mL), the solution adjusted to 0.01 M HCl and then placed in a water bath at 80°C for up to 24 h. To terminate the hydrolysis, the acid hydrolysate was cooled and pH was increased to pH 7 by addition of 10 M NaOH. Solutions were lyophilised and re-suspended in minimal dH$_2$O.

To obtain acid-hydrolysed G-fragments (AHGs) with acceptable number average degree of polymerisation as well as molecular weight distribution, the solutions were filtered once by dialysis to remove LMW oligomers and salts. Typically, the following reaction times and dialysis membrane cut-offs were used to produce AHGs with a desired molecular weight:

<table>
<thead>
<tr>
<th>Desired MW (g/mol)</th>
<th>Approx. reaction time (h:min)</th>
<th>Dialysis membrane cut-off (g/mol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2,500</td>
<td>21:00</td>
<td>1,000</td>
</tr>
<tr>
<td>7,500</td>
<td>9:45</td>
<td>2,000</td>
</tr>
<tr>
<td>15,000</td>
<td>5:30</td>
<td>8,000</td>
</tr>
</tbody>
</table>

The final products were lyophilised and characterised by FT-IR and gel permeation chromatography (GPC). The GPC system comprised of two TSK G5000PW$_{XL}$ and G3000PW$_{X}$ columns (Polymer Laboratories, UK) in series, mobile phase PBS (pH 7.4) and flow rate of 1 mL/min. Molecular weight and polydispersity were calculated relative to pullulan standards. Alginate standards are not commercially available, which necessitated the use of pullulan. These calibration standards do not give correct molecular weight for alginates since GPC separates according to hydrodynamic volume, which differs with varying macromolecular architecture. Alginates are more expanded than pullulans, resulting in a six-fold overestimate of alginate's molecular weight by GPC with pullulan. Consequently, a scaling factor...
(divide by 6) was applied to the apparent molecular weights calculated from pullulan calibration, to adjust for different macromolecular architecture of pullulan MW standards (Andersen T., et al., 2012, Alginates as biomaterials in tissue engineering. Carbohydrate Chemistry: Chemical and Biological Approaches, Vol. 37, 232-233/)

Samples for GPC were prepared in PBS (3 mg/mL) and the eluate was monitored using a differential refractometer (Optilab t-Rex (Wyatt, UK)). PL Caliber Instrument software, version 7.0.4, from Polymer Laboratories (UK) was used for data analysis.

Acid-hydrolysed G-fragments (AHGs) were generated with molecular weights between 2,500-26,000 g/mol (polydispersity 2.5-3.5). Typical characteristics of AHGs used in these studies are summarised in the table below.

<table>
<thead>
<tr>
<th>Name</th>
<th>Apparent molecular weight (g/mol)*</th>
<th>PDI</th>
<th>DPn</th>
</tr>
</thead>
<tbody>
<tr>
<td>OligoG</td>
<td>15,600 [2,600]</td>
<td>1.8</td>
<td>13</td>
</tr>
<tr>
<td>'2.5k'</td>
<td>15,000 [2,500]</td>
<td>1.4</td>
<td>13</td>
</tr>
<tr>
<td>'6k'</td>
<td>36,207 [6,035]</td>
<td>4.0</td>
<td>30</td>
</tr>
<tr>
<td>'7.5k'</td>
<td>42,000 [7,000]</td>
<td>2.6</td>
<td>35</td>
</tr>
<tr>
<td>'9k'</td>
<td>52,000 [8,670]</td>
<td>3.0</td>
<td>45</td>
</tr>
<tr>
<td>'13.5k'</td>
<td>81,543 [13,590]</td>
<td>2.9</td>
<td>68</td>
</tr>
<tr>
<td>'15k'</td>
<td>72,000 [12,000]</td>
<td>3.5</td>
<td>60</td>
</tr>
<tr>
<td>'16k'</td>
<td>93,500 [15,580]</td>
<td>3.6</td>
<td>81</td>
</tr>
<tr>
<td>'20k'</td>
<td>119,362 [19,894]</td>
<td>3.1</td>
<td>100</td>
</tr>
<tr>
<td>'26k'</td>
<td>152,500 [25,420]</td>
<td>3.5</td>
<td>132</td>
</tr>
<tr>
<td>PRONOVA UP MVG*</td>
<td>651,000 [108,500]</td>
<td>2.5</td>
<td>565</td>
</tr>
</tbody>
</table>

*relative to pullulan MW standards; value in [ ] indicates estimated actual MW after applying scaling factor to adjust for different macromolecular architecture of pullulan MW standards.

+Elutes in void volume, therefore MW is likely underestimated.
OligoG CF-5/20 for conjugation was produced as described previously (Khan et al. 2012, Antimicrobial Agents and Chemotherapy 56(10), 5134-5141). OligoG is a 5-20mer alginate oligomer with at least 85%G residues.

**Ester conjugation (E*)**

Briefly, for 2,500 g/mol AHG conjugation to bacitracin, alginate oligomer (200 mg, 0.08 mmol) was dissolved under stirring in anhydrous DMF (4 mL) (or anhydrous DMSO for Batches 3 and later) in a 10 mL round-bottomed flask. To this, DCC (16.5 mg, 0.08 mmol), DMAP (1.6 mg, 0.01 mmol) and bacitracin (37.5 mg, 0.03 mmol; Sigma) were added, and the reaction allowed to proceed at room temperature overnight, under stirring. To stop the reaction, the mixture was poured into excess chloroform (up to 20 mL), then the resulting precipitate was collected by filtration, re-dissolved in distilled water (dH₂O, 2 mL) and purified by FPLC (see below).

**Amide conjugation (TV)**

Briefly, for 2,500 g/mol AHG conjugation to bacitracin, alginate oligomer (200 mg, 0.08 mmol) was dissolved under stirring in dH₂O (2 mL) in a 10 mL round-bottomed flask. To this, EDC (19.9 mg, 0.1 mmol) and sulfo-NHS (22.6 mg, 0.1 mmol) were added, and the mixture was left stirring for 15 min. Subsequently, bacitracin (37.5 mg, 0.03 mmol) was added, and the reaction mixture was left stirring for 2 h at room temperature, the stored at -20 °C until purification by FPLC (see below).

**Purification of conjugates by FPLC**

Conjugates were purified from the reaction mixture by fast protein liquid chromatography (FPLC) (AKTA FPLC; Amersham Pharmacia Biotech, UK) using a pre-packed HiLoad Superdex 75 16/600 PG column with a UV detector and data analysis using Unicorn 4.0 software (Amersham Pharmacia Biotech, UK). Samples of the reaction mixture (2 mL) were injected into a 2 µL loop using PBS (pH 7.4) at 0.5 mL/min as a mobile phase. Fractions (5 mL) were collected, dialysed against de-ionised water (8 water changes) and assayed for protein content (BCA assay).
before pooling fractions containing conjugate. The final conjugate was lyophilised and stored at -20 °C.

**Example 2 - Characterisation of alginate oligomer-bacitracin conjugates**

**Purity, molecular weight and drug content**

Alginate oligomer-bacitracin conjugates were characterised by FPLC and GPC to assess purity and estimate molecular weight, and the total drug content of the conjugate was determined by the BCA assay using free drug as calibrant.

The FPLC system described above for purification was used again for final conjugate characterisation, with a pre-packed Superdex 75 10/300 GL column. Samples (200 µL) were dissolved in PBS (pH 7.4) and injected into a 100 mL loop at 0.5 mL/min. The GPC system described above as used again for final conjugate characterisation, and the same scaling factor was applied.

**Results**

Using these alginate oligomers, a library of bacitracin-alginate oligomer conjugates has been prepared, with a typical reaction yield of -40%, with molecular weights of 19,500-83,250 g/mol (relative to pullulan molecular weight standards); containing 1-7% w/w drug loading (equivalent to 3-5 oligomers: 1 bacitracin molecule).
**Batch 1**

<table>
<thead>
<tr>
<th>Conjugate</th>
<th>Initial drug ratio (% w/w)</th>
<th>Drug loading (% w/w)</th>
<th>Molar ratio (1 antibiotic: x AHG)</th>
<th>Molecular weight (g/mol)</th>
<th>PDI</th>
<th>Free drug (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OligoG-ESTER-bacitracin</td>
<td>18.2</td>
<td>6.8 (37%)</td>
<td>7.80</td>
<td>19,500</td>
<td>2.0</td>
<td>62.1</td>
</tr>
<tr>
<td>6k AHG-ESTER-bacitracin</td>
<td>7.9</td>
<td>3.7 (47%)</td>
<td>6.17</td>
<td>42,250</td>
<td>2.9</td>
<td>41.3</td>
</tr>
<tr>
<td>13.5k AHG-ESTER-bacitracin</td>
<td>3.5</td>
<td>1.0 (29%)</td>
<td>10.44</td>
<td>83,250</td>
<td>3.6</td>
<td>3.5</td>
</tr>
</tbody>
</table>

* Purified by ion exchange instead of size exclusion chromatography

**Batch 2**

<table>
<thead>
<tr>
<th>Conjugate</th>
<th>Drug loading (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.5k AHG-A-bacitracin</td>
<td>1.5</td>
</tr>
<tr>
<td>7.5k AHG-E-bacitracin</td>
<td>0.7</td>
</tr>
<tr>
<td>15k AHG-A-bacitracin</td>
<td>1.7</td>
</tr>
</tbody>
</table>

**Batch 4**

<table>
<thead>
<tr>
<th>Conjugate</th>
<th>Mn* (g/mol)</th>
<th>Mw* (g/mol)</th>
<th>PDI</th>
<th>Free drug (%)</th>
<th>Drug loading (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacitracin</td>
<td>9,250</td>
<td>10,750</td>
<td>1.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OligoG-A-bacitracin</td>
<td>10,750</td>
<td>27,250</td>
<td>2.5</td>
<td>0.7</td>
<td>4.3</td>
</tr>
<tr>
<td>OligoG</td>
<td>7,000</td>
<td>16,750</td>
<td>2.4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Example 3 - Antimicrobial activity

Bacterial isolates and strains:
The strains used for susceptibility testing include both culture collection strains and clinical isolates are recited below. Their known relevant genotypes and origin have been described by Khan et al. supra.

<table>
<thead>
<tr>
<th>Code</th>
<th>Isolate</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>V2</td>
<td><em>Pseudomonas aeruginosa</em> (301)</td>
<td>MDR-PSA isolate, multi drug resistant isolate defined as being resistant to pi</td>
</tr>
<tr>
<td></td>
<td></td>
<td>piperacillin, ceftazidime, imipenem, and gentamicin. Origin; Poland. Khan e</td>
</tr>
<tr>
<td></td>
<td></td>
<td>t al., supra.</td>
</tr>
<tr>
<td>V3</td>
<td><em>Klebsiella pneumoniae</em></td>
<td>Khan et al., supra.</td>
</tr>
<tr>
<td>V5</td>
<td><em>Escherichia coli</em></td>
<td>Khan et al., supra.</td>
</tr>
<tr>
<td>V19</td>
<td><em>Acinetobacter baumannii</em></td>
<td>Khan et al., supra.</td>
</tr>
<tr>
<td>E68</td>
<td><em>Staphylococcus aureus</em> NCTC 6571</td>
<td><em>Staphylococcus aureus</em> control Khan et al., supra.</td>
</tr>
<tr>
<td>E75</td>
<td><em>Staphylococcus aureus</em> NCTC 12493</td>
<td>Methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) control NCTC strain</td>
</tr>
</tbody>
</table>

Determination of antimicrobial activity

The MICs of alginate oligomers, bacitracin and alginate oligomer conjugates thereof were determined for isolates V2, V3, V5, V19, E68 and E75 using the broth microdilution method in accordance with standard guidelines (CLSI 2012). Test organisms were suspended in Mueller Hinton cation adjusted (MH) broth (100 µL, 1-5 x 10^4 CFU/mL) and incubated in 96-well microtitre plates in serial two-fold dilutions of the test compounds. The MIC was defined as the lowest concentration of test compound that produced no visible growth after 16-20 hours. Unless otherwise stated, results show median values of 3 experiments.
Results

None of the alginate fractions, or OligoG showed any antimicrobial activity, whereas unconjugated bacitracin showed high antimicrobial activity against *Staphylococcus aureus* (Gram positive) but not the Gram negative species tested (*Pseudomonas aeruginosa*, *Klebsiella pneumonia*, *Escherichia coli* and *Acinetobacter baumannii*). On the hand alginate oligomer conjugated bacitracin shows good antimicrobial activity against (lower MIC values) against both the Gram negative strains (in particular the *E. coli* strain) and the Gram positive strains.

Antimicrobial activity was greatest for conjugates containing low molecular weight alginate oligomers (including OligoG).

**Batch 1**

*MIC values (μg/mL) for each compound tested against a variety of bacteria*

<table>
<thead>
<tr>
<th>Drug loading (% w/w)</th>
<th>V2</th>
<th>V3</th>
<th>V5</th>
<th>V19</th>
<th>V33</th>
<th>E68</th>
<th>E75</th>
</tr>
</thead>
<tbody>
<tr>
<td>OligoG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9k AHG</td>
<td></td>
<td></td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
</tr>
<tr>
<td>13.5k AHG</td>
<td></td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
</tr>
<tr>
<td>16k AHG</td>
<td></td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
</tr>
<tr>
<td>20k AHG</td>
<td></td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
</tr>
<tr>
<td>26k AHG</td>
<td></td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
<td>&gt;1024</td>
</tr>
<tr>
<td>Bacitracin</td>
<td></td>
<td>&gt;128   &gt;128</td>
<td>&gt;128</td>
<td>&gt;128</td>
<td>64</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>OligoG-E-bacitracin</td>
<td>18.2</td>
<td>&gt;128</td>
<td>128</td>
<td>16</td>
<td>64</td>
<td>&gt;128</td>
<td>128</td>
</tr>
<tr>
<td>6k AHG-E-bacitracin</td>
<td>7.9</td>
<td>&gt;128</td>
<td>&gt;128</td>
<td>32</td>
<td>64</td>
<td>&gt;128</td>
<td>128</td>
</tr>
<tr>
<td>13.5k AHG-E-bacitracin</td>
<td>3.5</td>
<td>&gt;128</td>
<td>&gt;128</td>
<td>32</td>
<td>&gt;128*</td>
<td>&gt;128</td>
<td>&gt;128*</td>
</tr>
</tbody>
</table>
### Batch 2

MIC values (μg/mL) for each compound tested against a variety of bacteria (n=3, median)

<table>
<thead>
<tr>
<th>Conjugate</th>
<th>Drug loading (% w/w)</th>
<th>V2</th>
<th>V3</th>
<th>V5</th>
<th>V19</th>
<th>E68</th>
<th>E75</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacitracin</td>
<td></td>
<td>&gt;8192</td>
<td>&gt;8192</td>
<td>640</td>
<td>640</td>
<td>40</td>
<td>20</td>
</tr>
<tr>
<td>OligoG-A-bacitracin 3:1</td>
<td>3.2</td>
<td>&gt;256</td>
<td>&gt;256</td>
<td>32</td>
<td>128</td>
<td>&gt;256</td>
<td>&gt;256</td>
</tr>
<tr>
<td>OligoG-E-bacitracin 3:1</td>
<td>0.9</td>
<td>&gt;256</td>
<td>&gt;256</td>
<td>16</td>
<td>128</td>
<td>&gt;256</td>
<td>128</td>
</tr>
<tr>
<td>OligoG-A-bacitracin 2:1</td>
<td>1.1</td>
<td>&gt;256</td>
<td>&gt;256</td>
<td>32</td>
<td>256</td>
<td>&gt;256</td>
<td>128</td>
</tr>
<tr>
<td>OligoG-E-bacitracin 2:1</td>
<td>1.9</td>
<td>&gt;256</td>
<td>&gt;256</td>
<td>16</td>
<td>128</td>
<td>&gt;256</td>
<td>256</td>
</tr>
<tr>
<td>OligoG-A-bacitracin 1:1</td>
<td>5.0</td>
<td>&gt;256</td>
<td>&gt;256</td>
<td>64</td>
<td>256</td>
<td>&gt;256</td>
<td>256</td>
</tr>
<tr>
<td>OligoG-E-bacitracin 1:1</td>
<td>0.6</td>
<td>&gt;256</td>
<td>&gt;256</td>
<td>64</td>
<td>256</td>
<td>&gt;256</td>
<td>128</td>
</tr>
<tr>
<td>7.5k AHG-A-bacitracin</td>
<td>1.5</td>
<td>&gt;256</td>
<td>&gt;256</td>
<td>32</td>
<td>256</td>
<td>&gt;256</td>
<td>&gt;256</td>
</tr>
<tr>
<td>7.5k AHG-E-bacitracin</td>
<td>0.7</td>
<td>&gt;128</td>
<td>&gt;128</td>
<td>128</td>
<td>&gt;128</td>
<td>-</td>
<td>&gt;256</td>
</tr>
<tr>
<td>15k AHG-A-bacitracin</td>
<td>1.7</td>
<td>&gt;256</td>
<td>&gt;256</td>
<td>128</td>
<td>256</td>
<td>256</td>
<td>&gt;256</td>
</tr>
<tr>
<td>OligoG-A-bacitracin 3:1</td>
<td>3.2</td>
<td>&gt;256</td>
<td>&gt;256</td>
<td>32</td>
<td>128</td>
<td>&gt;256</td>
<td>&gt;256</td>
</tr>
<tr>
<td>OligoG-E-bacitracin 3:1</td>
<td>0.9</td>
<td>&gt;256</td>
<td>&gt;256</td>
<td>16</td>
<td>128</td>
<td>&gt;256</td>
<td>128</td>
</tr>
</tbody>
</table>
CLAIMS

1. A bacitracin-alginate oligomer conjugate comprising a bacitracin-class antibiotic connected covalently to at least one alginate oligomer via a direct covalent bond or a covalent molecular linker, or a pharmaceutically acceptable salt, solvate, hydrate, diastereoisomer, tautomer, enantiomer or active metabolite thereof.

2. The bacitracin-alginate oligomer conjugate of claim 1, wherein said bacitracin-class antibiotic is selected from bacitracin A1, A2, B1, B2, B3, C, D1, D2, D3 and E and functionally equivalent derivatives thereof.

3. The bacitracin-alginate oligomer conjugate of claim 1 or claim 2, wherein said bacitracin-class antibiotic is represented by Formula II

\[
\]

wherein Leu is leucine; Glu is glutamic acid; Lys is lysine; Orn is ornithine; Phe is phenylalanine; His is histidine; Asp is aspartic acid; Asn is asparagine; Y is valine, isoleucine, leucine or 5-methylene-isoleucine; Z is valine, isoleucine, leucine or 5-methylene-isoleucine; and X is W[11]-Cys[21] or V[11]-Thz[21]; wherein

W is valine, isoleucine, leucine or 5-methylene-isoleucine and Cys is cysteine; and

V is

\[
\text{H}_2\text{N-C(R)H-}
\]

wherein R is the side chain of valine, isoleucine, leucine or 5-methylene-isoleucine; and

\[
\text{Thz is a thiazoline ring (} \text{)} \text{ which is } 2' \text{ coupled to } V \text{ and } 4' \text{ coupled to the a-carbon of Leu}[3],
\]
wherein none or one or more, of amino acids Leu[3], Glu[4], Orn[7], Phe[9], His[10] or Asp[11] is replaced by another amino acid residue which may be selected from natural or non-genetically encoded amino acids.

4. The bacitracin-alginate oligomer conjugate of claim 3, wherein said natural or non-genetically encoded amino acid is selected from leucine, threonine, acid, phenylalanine, arginine, histidine, lysine, asparagine, serine, cysteine, homolysine, ornithine, diaminobutyric acid (e.g. α,γ-diaminobutyric acid), diaminopimelic acid, diaminopropionic acid, homocysteine, trimethyllysine, trimethylornithine, 4-aminopiperidine-4-carboxylic acid, 4-amino-1-carbamimidoylpiperidine-4-carboxylic acid and 4-guanidinophenylalanine.

5. The bacitracin-alginate oligomer conjugate of any one of claims 1 to 4, wherein said bacitracin-class antibiotic is selected from bacitracin A (A1 and/or A2) and bacitracin B (B1 and/or B2).

6. The bacitracin-alginate oligomer conjugate of any one of claims 1 to 5, wherein said bacitracin-class antibiotic is complexed with divalent metal cations, e.g. Zn²⁺, Mg²⁺, Mn²⁺, and Co²⁺

7. The bacitracin-alginate oligomer conjugate of any one of claims 1 to 6, wherein said alginate oligomer has an average molecular weight of less than 35,000 Daltons, preferably less than 30,000, 25,000 or 20,000 Daltons.

8. The bacitracin-alginate oligomer conjugate of any one of claims 1 to 7, wherein the alginate oligomer has a degree of polymerisation (DP), or a number average degree of polymerisation (DPn) of

(i) 4 to 100, 4 to 75, 4 to 50, 4 to 35, 4 to 30, 4 to 25, 4 to 22, 4 to 20, 4 to 18, 4 to 16 or 4 to 14.

(ii) 6 to 50, 6 to 35, 6 to 30, 6 to 25, 6 to 22, 6 to 20, 6 to 18, 6 to 16 or 6 to 14,

(iii) 8 to 50, 8 to 35, 8 to 30, 8 to 25, 10 to 25, 10 to 22, 10 to 20, 10 to 18, or 10 to 15, or
(iv) 20 to 100, 20 to 90, 20 to 80, 20 to 75, 20 to 70, 20 to 65, 20 to 60, 20 to 55, 20 to 50, 20 to 45, 20 to 40, 20 to 35, 20 to 30 or 20 to 25, or
(v) 30 to 100, 30 to 90, 30 to 80, 30 to 75, 30 to 70, 30 to 65, 30 to 60, 30 to 55, 30 to 50, 30 to 45, 30 to 40 or 30 to 35.

9 The bacitracin-alginate oligomer conjugate of any one of claims 1 to 8, wherein the alginate oligomer has at least 70% G residues, or at least 80%, or at least 85%, or at least 90%, or at least 95% G residues.

10. The bacitracin-alginate oligomer conjugate of claim 9, wherein at least 80% of the G residues are arranged in G-blocks.

11. The bacitracin-alginate oligomer conjugate of any one of claims 1 to 8, wherein the alginate oligomer has at least 70% M residues, or at least 80%, or at least 85%, or at least 90%, or at least 95% M residues.

12. The bacitracin-alginate oligomer conjugate of claim 11, wherein at least 80% of the M residues are arranged in M-blocks.

13. The bacitracin-alginate oligomer conjugate of any one of claims 1 to 12, wherein said direct covalent bond is part of an ester, carbonate ester, orthoester, ketal, hemiketal, ether, acetal, hemiacetal, peroxy, methylenedioxy, amide, amine, imine, imide, azide, azo, oxime, sulfide, disulfide, sulfinyl, sulfonyl, carbonothioyl, thioester, phosphine or phosphodiester functional group.

14. The bacitracin-alginate oligomer conjugate of claim 13, wherein said direct covalent bond is part of an ester or an amide.

15. The bacitracin-alginate oligomer conjugate of any one of claims 1 to 12, wherein said covalent linker is or comprises molecular groups selected from:
   (i) an amino acid or a peptide;
   (ii) monosaccharide or an oligosaccharide other than guluronate or mannuronate or polymers formed therefrom;
   (iii) a ribonucleotide or a deoxyribonucleotide;
(iv) a straight chain, branched or cyclic, substituted or unsubstituted, alkyl, alkenyl or alkynl group;

(v) an acetyl, succinyl, aconityl (c/s or trans), glutaryl, methylsuccinyl, trimellityl cysteamine, penicillamine, N-(2-mercaptopropionyl)glycine, 2-mercaptopropionic acid, homocysteine, 3-mercaptopropionic acid or deamino-penicillamine group

16. The bacitracin-alginate oligomer conjugate of any one of claims 1 to 15, wherein said direct covalent bond, a functional group containing said covalent bond or said covalent molecular linker is
   (i) acid labile;
   (ii) sensitive to reactive oxygen species; and/or
   (iii) degraded by an enzyme secreted by a bacterium or an immune cell.

17. The bacitracin-alginate oligomer conjugate of any one of claims 1 to 16, wherein said conjugate consists of at least one alginate oligomer covalently bonded to a bacitracin-class antibiotic via an ester bond formed from a carboxyl group on the alginate and hydroxyl group on the bacitracin.

18. The bacitracin-alginate oligomer conjugate of any one of claims 1 to 16, wherein said conjugate consists of at least one alginate oligomer covalently bonded to a bacitracin-class antibiotic via an amide bond formed from a carboxyl group on the alginate and an amine group on the bacitracin.

19. The bacitracin-alginate oligomer conjugate of any one of claims 16 to 18, wherein the alginate oligomer contains 2 to 100 monomer residues.

20. The bacitracin-alginate oligomer conjugate of any one of claims 16 to 19, wherein the alginate oligomer has at least 70% G residues.

21. A pharmaceutical composition comprising a bacitracin-alginate oligomer conjugate as defined in any one of claims 1 to 20 and a pharmaceutically acceptable excipient, carrier or diluent.
22. A method for the preparation of a bacitracin-alginate oligomer as defined in any one of claims 1 to 20, said method comprising

   (ia) providing an alginate oligomer and a bacitracin-class antibiotic and forming a direct covalent bond between two molecular groups thereon; or
   (ib) providing an alginate oligomer, a bacitracin-class antibiotic and a covalent molecular linker and forming a direct covalent bond between two molecular groups on the alginate oligomer and the linker molecule and forming a direct covalent bond between two molecular groups on the bacitracin-class antibiotic and the linker molecule; or
   (ic) providing an alginate oligomer and a bacitracin-class antibiotic wherein one or both carry a covalent molecular linker molecule covalently bonded thereto and covalently linking the alginate oligomer to the bacitracin-class antibiotic via at least one of the linker molecules; and optionally
   (ii) separating at least a portion of the bacitracin-alginate oligomer conjugate from the reaction mixture.

23. The method of claim 22, said method comprising

   (i) providing an aqueous solution of an alginate oligomer having an available carboxyl group;
   (ii) contacting said alginate solution with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDO) in an amount and under conditions sufficient to activate at least one carboxyl group in the alginate oligomer;
   (iii) optionally contacting said carboxyl activated alginate oligomer with sulfo N-hydroxysuccinimide (sulfo-NHS) in an amount and under conditions sufficient to form an amine-reactive sulfo-NHS ester;
   (iv) contacting said carboxyl activated alginate oligomer of step (ii) or the amine-reactive sulfo-NHS ester of step (iii) with a bacitracin-class antibiotic having an available primary amine group in an amount and under conditions sufficient to form an amide bond between the alginate oligomer and the bacitracin-class antibiotic; and
   (v) separating at least a portion of the bacitracin-alginate oligomer conjugate from the reaction mixture.

24. The method of claim 22, said method comprising
(i) providing a solution of an alginate oligomer having an available carboxyl group, preferable an organic (e.g. DMF and/or DMSO) solution;

(ii) contacting said alginate solution with dicyclohexylcarbodiimide (DCC) in an amount and under conditions sufficient to form an O-acylisourea intermediate;

(iii) contacting said O-acylisourea intermediate with an bacitracin-class antibiotic having an available hydroxyl group and 4-N,N-dimethylaminopyridine (DMAP) in amounts and under conditions sufficient to form an ester bond between the alginate oligomer and the bacitracin-class antibiotic; and

(iv) separating at least a portion of the bacitracin-alginate oligomer conjugate from the reaction mixture;

wherein steps (ii) and (iii) may be performed simultaneously.

25. A bacitracin-alginate oligomer conjugate as defined in any one of claims 1 to 20 of a pharmaceutical composition as defined in claim 21 for use in the treatment of prevention of a bacterial infection.

26. A method for the treatment or prevention of a bacterial infection in a subject with, suspected to have, or at risk of, a bacterial infection, said method comprising administering to said subject an effective amount of a bacitracin-alginate oligomer conjugate as defined in any one of claims 1 to 20 or the pharmaceutical composition as defined in claim 21.

27. The bacitracin-alginate oligomer conjugate or pharmaceutical composition for the use of claim 25 or the method of claim 26 wherein the bacterial infection is

(i) in a wound, preferably a chronic wound;

(ii) a respiratory infection in a subject suffering from an underlying respiratory disorder or condition, preferably selected from CF, COPD/COAD, or asthma;

(iii) a device related infection associated with implantable or prosthetic medical devices; or

(iv) a systemic infection or an infection of multiple loci within or on the subject.
28. The bacitracin-alginate oligomer conjugate or pharmaceutical composition for the use of claim 25 or claim 27 or the method of claim 26 or 27, wherein the infection is a Gram negative bacterial infection.
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>wo 2010/139956 AI (ALGI PHARMA AS [NO]; ONSOYEN EDVAR [NO]; MYRVOLD ROLF [NO]; DESSEN) 9 December 2010 (2010-12-09) page 3, line 12 - page 4, line 8 page 17, line 1 - line 13 page 8, line 12 page 9, line 4 - page 15, line 7 page 20, line 24 - page 21, line 19 page 58, line 22 - line 30; claims; examples -----</td>
<td>1-28</td>
</tr>
<tr>
<td>Y</td>
<td>us 2014/364595 AI (BAPAT ABHIJIT S [IN] ET AL) 11 December 2014 (2014-12-11) paragraphs [0005] - [0034], [0066], [0095], [0107], [0119], [0165], [0277]; figure 22 -----</td>
<td>1-28</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:
  
  A: document defining the general state of the art which is not considered to be of particular relevance
  
  E: earlier application or patent but published on or after the international filing date
  
  L: document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason as specified
  
  O: document referring to an oral disclosure, use, exhibition or other means
  
  P: document published prior to the international filing date but later than the priority date claimed

  T: later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

  X: document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

  Y: document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

  A: document member of the same patent family

Date of the actual completion of the international search: 18 January 2018

Date of mailing of the international search report: 01/02/2018

Authorized officer: Steffen, Pierre

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016

Form PCT/ISA/210 (second sheet) (April 2005)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>US 3 952 092 A (BOWEN WILLIAM HENRY ET AL) 20 April 1976 (1976-04-20) example 12</td>
<td>1-28</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>wo 2010139956</td>
<td>09-12-2010</td>
<td>AU 2010255542 AI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2010255543 AI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR PI 1011248 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2764195 AI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2764197 AI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 102458474 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 102497883 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 2437783 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 2437784 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2437783 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2437784 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2442793 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2444541 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GB 2483203 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GB 2483413 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5202763 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5202764 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2012528840 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2012528841 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20120034680 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20120035166 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 2437783 E</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 2437784 E</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RS 53136 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RS 53139 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RU 2011148757 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RU 2011148758 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SI 2437783 T1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SI 2437784 T1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2012115803 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2012122768 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2015238520 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2010139956 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2010139957 A</td>
</tr>
</tbody>
</table>

| us 2014364595                          | 11-12-2014      | AU 2012272804 AI        | 16-01 -2014     |
|                                        |                 | BR 112013033239 A2      | 06-09 -2016     |
|                                        |                 | CA 2840215 AI           | 27-12 -2012     |
|                                        |                 | CN 103857440 A          | 11-06 -2014     |
|                                        |                 | EA 201490100 AI         | 28-11 -2014     |
|                                        |                 | EP 2723452 A2           | 30-04 -2014     |
|                                        |                 | JP 2014522816 A         | 08-09 -2014     |
|                                        |                 | KR 20140057414 A        | 12-05 -2014     |
|                                        |                 | NZ 619293 A             | 31-03 -2017     |
|                                        |                 | US 2014364595 AI        | 11-12-2014      |
|                                        |                 | WO 2012177986 A2        | 27-12 -2012     |

<p>| us 3952092                             | 20-04-1976      | AU 5659473 A            | 12-12 -1974     |
|                                        |                 | BE 800695 A             | 10-12 -1973     |
|                                        |                 | DE 2329253 A            | 13-12 -1973     |
|                                        |                 | ES 415753 A             | 16-06 -1976     |
|                                        |                 | FR 2187294 A            | 18-01 -1974     |
|                                        |                 | GB 1433593 A            | 28-04 -1976     |
|                                        |                 | IE 37742 BI             | 28-09 -1977     |
|                                        |                 | IT 1078724 B            | 08-05 -1985     |
|                                        |                 | NL 7307927 A            | 11-12 -1973     |
|                                        |                 | US 3952092 A            | 20-04 -1976     |
|                                        |                 | ZA 7303745 B            | 24-04 -1974     |</p>
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>